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Abstract 
Background:  
Exercise performance is reduced in individuals with moderate to severe cystic fibrosis 
(CF).  A ventilatory mechanical limitation, arterial hypoxemia, cardiovascular 
abnormalities, alteration in O2 uptake kinetics and reduced muscle strength may 
contribute to the reduced exercise performance in individuals with CF patients.  The 
purpose of this research was to compare the exercise response in patients with 
different CF severities using non- invasive methods, and examine the effect of exercise 
training with and without O2 supplementation on exercise performance.   
Methods:  
Study 1: Adults (n=33) with different severities of CF and healthy controls (n=34) had 
their body composition, and pulmonary function assessed, and performed a peak 
exercise test. 
Study 2: Adults (n=28) with different severities of CF and healthy controls (n=19) had 
their muscle strength, pulmonary function, body composition and V7O2peak assessed, 
and performed a submaximal exercise tests.   
Study 3: Adults with different severities of CF who were randomly assigned to a 
placebo (n=6) or O2 supplemental (O2Suppl) (n=5) group undertook interval training on 
a cycle ergometer 2 days/week for 8 weeks (single blind).  Body composition, 
pulmonary function, V7O2peak, muscle strength, time to complete a 6 minute walk and 
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performance during a constant work load submaximal tests were assessed before and 
after the training study. 
Results: 
Peak exercise capacity and muscle strength were reduced and O2 uptake 
kinetics was slower in CF patients than healthy controls.  The provision of 
supplemental O2 during training improved O2 uptake kinetics and resulted in a 
decrease in ventilation, respiratory rate and blood lactate levels during exercise. 
Conclusion:  
Depending on disease severity, the reduction in exercise capacity in CF patients 
is related to a reduced lean body mass, reduced gas exchange, ventilatory limitation, 
and an altered cardiovascular response.  The provision of supplemental O2 during 
exercise training may improve endurance capacity in patients with CF.   
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Chapter 1  
Introduction  
Cystic fibrosis (CF) is an autosomal recessive disease that occurs primarily in 
Caucasians, with a worldwide incidence rate of 1 in 2,500 to 3,000 live births.  It is the 
most common life-threatening inherited disease in Ireland [1] where the incident rate 
is the highest in the world, at 1 in 1,353.  Males and females are equally affected.  The 
development of sensitive diagnostic techniques and better supportive treatment in 
multidisciplinary CF care centres, have dramatically increased life expectancy of cystic 
fibrosis patients in Ireland.   
CF is caused by mutations in the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene on the long arm of chromosome 7 [14].  The CFTR gene codes 
for a protein that spans the apical membrane of epithelial cells lining the airways, 
pancreatic ducts, sweat ducts, intestines, biliary tree, and vas deferens, and normally 
regulates the transport of chlorine and other ions.  The chloride ion channel is 
important in producing sweat, mucus and digestive juices.  Normal levels of mucus 
provide the lungs with a protective mechanism to reduce the risk of infections.  In 
individuals with CF, the absence of this chloride ion channel affects the ability to 
transport salt and water into and out of cells, which in turn results in the production of 
dry, thick and sticky secretions that impairs mucociliary clearance (30).  A combination 
of mucus plaques and impaired mucociliary clearance establishes a breeding ground 
for bacterial infection, particularly in the lungs (13).  
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Although antibiotics may help to contain infections within the lungs, they 
usually fail to eradicate the organisms, and destruction of the airways is continual, 
eventually leading to bronchiolitis, bronchitis, bronchiectasis and eventually fibrosis 
and irreversible loss of pulmonary function.  Chronic lung infection is the principle 
cause of death in >90% of CF patients [2].  CF also increases susceptibility to 
malnutrition, pancreatic, liver and gall bladder disease, diabetes, male infertility, and 
poor growth.  Symptoms vary depending on age, prior treatment, types of infections 
encountered, environmental factors and the extent to which various organs are 
affected (20).   
Treatments for CF include a wide range of therapies based on current 
infection(s) and disease progression, and include drug based therapies, airway 
clearance mechanisms, implanted devices, nutritional interventions and exercise.  The 
severity of the illness increases with age, and treatments become progressively more 
expensive and more difficult to manage.  Patients with more severe CF symptoms may 
require hospitalization for organ transplantation (15) and palliative care.   
Exercise intolerance is a characteristic of CF [3].  Studies examining the 
physiological responses to exercise in CF patients began in the 1970’s (44).  Research in 
the late 1980’s showed that ventilation and mucus clearance could be improved with 
exercise (45).  Studies in the 1990’s started to examine the relation between indices of 
fitness and survival in CF patients.  Nixon et al., [46] found a significant relation 
between peak oxygen uptake (V7O2peak) and eight year survival in children with CF.  
Patients with a V7O2peak of ≥ 82% of predicted had an 83% chance of survival at 8 
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years.  The 8 year survival rate for patients with a V7O2peak of 59-81% of predicted was 
51% and 28% in those with a V7O2peak of ≤ 58% of predicted.  
The main symptoms of CF that limit exercise performance are dyspnea and 
fatigue.  Impaired lung gas exchange [4], different degrees of lung hyperinflation [5-7], 
and in more advanced disease, abnormalities of pulmonary circulation [9], may 
negatively impact on the ability to sustain exercise, especially as the disease becomes 
more progressive.  In addition to alterations in lung function, maladaptive changes in 
peripheral muscle size and function may also contribute to exercise intolerance in CF 
[8-10]. 
Understanding the exercise response in CF is important in order to design and 
implement appropriate lifestyle interventions.  Exercise intolerance in CF is complex 
and multi-factorial and is dependent on many factors including impaired respiratory 
system mechanics, arterial hypoxemia, peripheral skeletal muscle dysfunction and 
cardiovascular function.  These contributing factors are interdependent and the 
predominant contributing factor may vary among patients with different severities of 
CF.  The integrative response during cardiopulmonary exercise testing (CPET) and the 
assessment of muscle strength are non-invasive sensitive tools than can be used to 
detect abnormal function and exercise limitation in patients with mild, moderate and 
severe CF. 
Functional capacity as measured by V7O2peak is a significant predictor of 
survival in patients with CF [46].  A limitation of maximal testing is that it is dependent 
on disease status and motivation.  Oxygen uptake (V7O2) kinetics describes the rate of 
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V7O2 change at the onset of exercise and is used to determine an individual’s ability to 
adapt to changes in workrate (WR).  A slower response of oxygen uptake after an 
increase in exercise intensity results in a relatively higher oxygen deficit and oxygen 
debt, which has been linked to premature fatigue and reduced exercise time [131].   
Exercise training is an important component of care for patients with CF [11].    
Allowing CF patients to train for a longer duration at a high intensity may enhance the 
training effect.  Supplemental oxygen (O2) has recently been used to overcome the 
ventilatory limitation during an acute bout of submaximal [12] exercise and during an 
incremental maximal exercise test [4] in CF patients.  The provision of supplemental O2 
during exercise training could delay the ventilatory limitation during exercise without 
altering lung function or the maximum ventilatory capacity.  To date no studies have 
examined the effect of supplemental O2 during exercise training on endurance 
performance training in patients with CF.   
Study Aims 
The following series of studies will i) compare the exercise response in patients 
with different CF severities using non- invasive methods, and ii) examine the effect of 
exercise training with and without O2 supplementation on exercise performance.   
Objectives 
1. To determine the role of pulmonary function, arterial O2 saturation (SPO2%), 
muscle function and O2 pulse on maximal exercise capacity in adults with mild, 
moderate and severe CF  
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2. To compare body composition, peak exercise capacity, muscle strength, and O2 
uptake kinetics in adults with CF and healthy individuals.   
3. To compare the effects of an 8 week interval training programme with and 
without O2 supplementation on training volume, V7O2 peak, O2 uptake kinetics, 
endurance performance and muscle strength in CF patients.   
 
Hypothesis 
1. Ventilatory mechanical limitation and pulmonary gas exchange abnormality 
will contribute to the reduced peak exercise capacity in CF patients with 
moderate and severe disease. 
2. Cardiovascular abnormalities will contribute to the reduced peak exercise 
capacity in CF patients with FEV1 <30% of predicted. 
3. Compared to healthy individuals, patients with moderate to severe CF will 
have a reduction in muscle strength, and prolonged O2 uptake kinetics, and 
increased circulating levels of blood lactate during constant load exercise  
4. Compared to healthy individuals, patients with mild CF will have similar 
muscle strength, O2 uptake kinetics, and blood lactate levels during 
constant load exercise. 
5. Compared to interval training using normal atmospheric oxygen 
concentration, interval training with supplemental O2 will result in a greater 
 21 
training volume, and a greater improvement in V7O2peak, O2uptake kinetics, 
endurance performance, and muscle strength in CF patients 
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Chapter 2  
Literature of Review  
Overview of Cystic Fibrosis in Ireland 
Cystic fibrosis is an autosomal recessive condition caused by a variable 
mutation in the CFTR gene [13].  The normal CFTR protein product is an ion channel 
that is expressed in endothelial cells of the umbilical vein, lung microvasculature, red 
blood cells, pancreas, lung epithelia, sweat gland, colon, parotid gland, liver, proximal 
tubules of the kidney, heart myocytes, skeletal muscle and hypothalamus.  In CF, the 
inherited CF gene directs the body's epithelial cells to produce a defective form of the 
CFTR protein [14] that disrupts epithelial ion transport and can lead to respiratory 
failure, pancreatic insufficiency, and infertility, as well as a range of other defects. 
CF is the most common life-threatening inherited disease in Ireland [1].  The 
incidence of CF is 1 per 1353 births, which ranks Ireland number one in the world.  On 
a global scale, Ireland also has i) the highest number of CF carriers per head of the 
population with 1 in 19 people carrying a single copy of the defective CFTR gene, and 
ii) the largest proportion of families with more than one child suffering from CF.   
Over 50 mutations of the CFTR gene are represented in Ireland.  The ∆F508, is 
the common mutation among the Irish population, with 64% and 94% of the 
population homozygous and heterozygous respectively, for this abnormal allele [1].  
The G55ID mutation is the second most frequently-occurring mutation in Ireland.  The 
clinical course of patients with CF is variable and is determined by many interacting 
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factors.  However, advances in the management of CF have led to a significant 
improvement in survival.  
Cystic Fibrosis Transmembrane Conductance Regulator 
Structure and Function of CFTR 
Epithelial cells that line the airways have ion channels that allow sodium ions to 
flow into the cell and chloride ions out of the cell into the mucus on the airway surface.  
Along with an ion pump, the action of the channels results in an excess of chloride ions 
in the mucus.  This creates an ionic gradient that promotes the movement of water 
through the gaps between the cells, which keeps the mucus moist.  
The chloride channel is made from a protein called CF transmembrane 
regulator (CFTR) protein.  It is a 1480 amino acid membrane bound glycoprotein and is 
a member of the ABC transporter family.  It is located predominantly in the apical 
membrane of epithelia, and is composed of two membrane-spanning domains, two 
nucleotide-binding domains, and a regulatory domain.  The regulatory domain is 
phosphorylated by protein kinase A (PKA) via a cyclic adenosine monophosphate 
(cAMP) dependent pathway.  The subsequent binding and cleaving of ATP at adjacent 
sites regulates the opening and closing of the channel, as shown in Figure  2.1.  
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Figure  2.1: Binding and cleaving of ATP at adjacent sites 
The CFTR gene is found in region q31.2 on the long arm of human chromosome 
7.  The normal allelic variant is about 250,000 base pairs long and contains 27 exons.  
Mutation of the CFTR gene alters the production, structure, or stability of the chloride 
channel resulting in CF [14]. 
Mutations in CFTR and Consequences 
More than 1000 mutations of the CFTR gene have been identified in people 
with CF [15].  These mutations can be divided into 5 classes (  Figure  2.2).  
Class I mutations cause defective protein production.  These mutations result in 
the production of little or no CFTR chloride channels (G542X, 3905 ins T).  Class II 
mutations are associated with defective protein processing, as evident in the ∆F508 
mutation.  This mutation results in the deletion of a single amino acid at position 508 
in the CFTR protein.  The resulting abnormal channel is inadequately processed in the 
endoplasmic reticulum and does not reach the cell membrane to transport chloride 
ions [14, 17].  The ∆F508 mutation is found in approximately 70% of defective CFTR 
alleles of patients with CF in the US [14].  Class III mutations are associated with 
defective regulation.  Some mutations cause total loss of ability to be stimulated by 
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ATP, and in others this ability is reduced (G55ID, G55IS).  Class IV mutations are 
associated with the defective conductance of chlorine ions.  Some studies have shown 
that even in the presence of class IV mutations the CFTR chloride channels are capable 
of generating normal functional cAMP-regulated chloride channels (R117H, R334W).  
Finally, class V mutations result in a reduction in the number of CFTR transcripts [18].  
 
  Figure  2.2: Categories of CFTR mutations 
Genotype-Phenotype in CF  
Cystic fibrosis is characterized by a large variability of clinical expression. 
Different mutations have varying effects on CFTR function and can result in 
phenotypes that range from mild to severe [16].  For example, the ∆F508 mutation is  
associated with a severe phenotype, while other mutations such as R117H, R334W are 
associated with a milder phenotype [19-20].  In addition, there is substantial variation 
in disease expression among patients carrying the same mutation.  
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Clinical Outcome and CFTR Function in the Lungs  
Patients homozygous for the ∆F508 mutation have earlier onset of the disease, 
higher sweat chloride level, and pancreas insufficiency.  However, despite the severe 
nature of this mutation, the severity of pulmonary disease varies among patients. 
Attempts to link the CFTR mutation to severity of lung disease have been unsuccessful 
in children and young adults with CF [21-22].  In contrast, adults with CF who have 
CFTR class I or II mutations on both chromosomes have a reduced forced expiratory 
volume in one second (FEV1), reduced forced vital capacity (FVC), and a greater loss of 
pulmonary function during a 10 year follow up period [23].  In addition, patients in the 
CFTR class I or II mutations have a higher risk of developing moderate to severe 
pulmonary disease than patients with at least one CFTR functional class III, IV or V 
mutation.  
Chronic pulmonary infection is the hallmark of CF and respiratory failure is the 
leading cause of death in 90% of CF patients.  Pseudomonas aeruginosa (P. aeruginosa) 
is the most common pathogen responsible for pulmonary infection in CF.  Up to 80% of 
patients with CF are eventually infected with P. aeruginosa.  CF patients who are 
homozygous for the ∆F508 mutation, have a higher risk for initial P. aeruginosa airway 
infection than patients with class IV CFTR mutations [24].  In contrast, the prevalence 
of other common pathogens, such us S. aureus and H. influenzae, are similar across all 
the CFTR mutations.  Burkholderia cepacia (B. cepacia) is a gram-negative bacteria that 
is also associated with severe airway infection as CF progresses.  It is associated with B. 
cepacia syndrome leading to high fever, bacterial infection and rapid progression to 
severe pneumonia and death.  However, studies have found that B. cepacia is not a 
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single species but rather a group of closely related species, known as genomovar, 
called B. cepacia complex.  At least nine distinctive genomovars of B. cepacia have 
been identified [25-26].  The majority of CF airways infections with B. cepacia complex 
are caused by genomovar II, III, and V [27], and the majority of severe infections result 
from genomovar III [28]. 
Acute infection is generally associated with inflammation.  The airway epithelial 
cells, which normally expresses the CFTR, directs the inflammatory response.  Defects 
in CFTR are associated with increased production of pro-inflammatory mediators 
including IL-8, which stimulates the influx of neutrophils into the airway [29].  These 
neutrophils are the primary effector cells responsible for the pathological 
manifestations of CF lung disease.  Neutrophils release large amounts of proteases 
(especially elastase) that further stimulate the inflammatory response and the 
production of O2 free radicals.  Other mediators that play an important role in 
neutrophil influx in the lung are tumour necrosis factor alphas (TNF-α), IL-1, and IL-6 
[30].  Each of these inflammatory mediators are present in high concentrations in CF 
sputum [31].  Although these mediators may be beneficial in containing bacterial 
infection by stimulating host defences, their continued overproduction contributes to 
the pathologic findings in CF.  TNF-α enhanced neutrophil oxidation may be 
responsible for the cachexia associated with CF [32].   
For a given bacterial load, the inflammatory response is up to 10 times greater 
in a CF patient than in an individual with a lower respiratory tract infection, but 
without the disease.  Chronic bacterial infection and excessive inflammation are 
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responsible for structural damage in the small airways and parenchyma (complex 
system consisting of alveolar walls, the air-liquid interface and interstitial cells) in CF 
patients.   
From early childhood, parts of the airways in CF patients become thickened and 
dilated (bronciectasis).  Eventually the lung parenchyma becomes affected by 
atelectasis (collapse of the alveoli) resulting in a reduction in lung compliance and an 
increased resistance to blood flow in the pulmonary capillaries of the affected alveoli 
[28-29].  The progressive structural lung damage eventually leads to end-stage lung 
disease, which is characterized by a reduction in pulmonary diffusion capacity (DC) 
resulting in hypoxemia and an increase in the work of breathing.  Patients with 
advanced CF are often O2 dependent with carbon dioxide (CO2) retention.  They also 
have an increase in the frequency of exacerbations.   
Clinical Outcome and CFTR Function in other Organs  
Pancreatic enzymes that are involved in the digestion of food enter the 
intestine through the pancreatic ducts.  In CF, the pancreas produces thick secretions, 
which block the ducts, resulting in the retention of proenzymes which in turn leads to 
tissue destruction and fibrosis [33].  CF patients are therefore unable to digest and 
absorb food properly, leading to weight loss, protein deficiency and deficiency of the 
fat-soluble vitamins A, D, E, and K [34].  Malnutrition also contributes to the inability to 
supply energy to meet the requirements associated with lung infections.  Since lung 
infections can lead to reduced appetite and emesis, malnutrition is further enhanced.  
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Both complications combine to decrease total body mass and lean body mass (LBM) in 
CF patients [35]. 
The extent of pancreatic disease also varies among CF patients.  Most CF 
patients suffer from pancreatic insufficiency (PI), but approximately 15% have 
sufficient pancreatic function (PS) to permit normal digestion [21].  There is some 
evidence for a genetic basis for the severity of pancreatic disease.  More than 50% of 
the CF-PI patients are homozygous for ∆F508, while none of the CF-PS patients are 
homozygous for ∆F508, suggesting that ∆F508 is associated with PI [21].  PI is also 
associated with diabetes.  PI is very common in men and women with diabetes [36-37].  
Few studies have found a relation between liver disease and CFTR genotype 
[22, 38].  CF patients who have PI and carry mutations associated with a severe or 
variable genotype are at increased risk of developing liver disease [38].  The prevalence 
of abnormal liver function in class IV patients is approximately one third of that found 
in patients homozygous for ∆F508 [22]. 
Recently, Lamhonwah et al., [39] found that CFTR is expressed in the 
sarcoplasmic reticulum of human skeletal muscle.  In mice, the lack of CFTR in skeletal 
muscle has been related to an increase in inflammatory/atrophic gene expression and 
increased diaphragmatic weakness during pulmonary infection [40].  
Treatment 
There is currently no cure for CF.  Pulmonary disease is the single most 
important contributing factor to the increased morbidity and mortality associated with 
CF [33].  While the effect on other organ systems can be contained, arresting the 
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decline in lung function presents the biggest challenge to clinical management of the 
disease [33].  Treatment of the lung disease is undertaken with a variety of modalities, 
including mechanical airway clearance, antimicrobials, bronchodilators, supplemental 
oxygen, mucolytics, and a variety of other novel treatments including gene therapy.  
Treatment for CF patients is primarily directed at controlling lung function, 
promoting mucus clearance from the lungs, nutritional supplementation and 
improving functional status.  Pancreatic enzymes are taken at meal times to aid 
digestion.  Daily physiotherapy promotes mucus clearance from the lungs and is the 
cornerstone of managing established pulmonary disease in CF.  Whenever possible, 
lung infections are treated with antimicrobials.  Systemic corticosteroids are used to 
treat airway inflammation [41].  They may also attenuate the decline in lung function 
[42].  However, chronic use of corticosteroids can reduce muscle mass, negatively 
impact on muscle function [36], increase body weight due to an increase in fat mass, 
and cause diabetes.  Ideally, treatment with corticosteroids should only be used as a 
short term intervention during pulmonary exacerbations [41].  
Depletion of the airway surface liquid (ASL) is an important factor that also 
contributes to abnormal mucus clearance in CF.  A simple and attractive way to restore 
ASL is to use an osmotic liquid that draws water into the ASL, therefore minimizing the 
defect in mucocillary clearance.  Hypertonic saline (HS) has been shown to improve 
FEV1 [37] and reduce pulmonary exacerbation in older patients with CF.  Although 
much progress has been made in gene therapy, it is presently not a treatment option 
for patients with CF [43].  Targets for CFTR pharmacotherapy include activation of 
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chloride secretion and inhibition of sodium absorption.  However, results to date have 
not been promising [43]. 
Peak V9O2 and Prognosis in CF 
Exercise intolerance is a characteristic of CF.  Studies examining the 
physiological responses to exercise in CF patients began in the 1970’s [44].  Research in 
the late 1980’s found that pulmonary ventilation and mucus clearance could be 
improved with exercise training [45].  Studies in the 1990’s started to examine the 
relation between indices of fitness and survival in CF patients.  Nixon et al., [46] found 
a significant relation between V7O2peak and eight-year survival in children with CF after 
adjusting for age, gender, colonization of the respiratory airways by P. cepacia, body 
mass index (BMI), pulmonary function and end tidal PCO2 (PETCO2) at peak exercise.  
Patients with a V7O2peak ≥ 82% of predicted had an 83% chance of survival at 8 years.  
The 8-year survival rate for patients with a V7O2peak of 59-81% of predicted was 51% 
and 28% in those with a V7O2peak of ≤ 58% of predicted. 
More recently, Pianosi et al., [47] performed an annual pulmonary function and 
maximal exercise test in 28 CF children between the age of 8-17 years to determine 
the relation between changes in lung function and V7O2peak and survival over 7-8 
years.  Initial V7O2peak was not predictive of 7-8 year survival.  In contrast, the rate of 
decline in V7O2peak and final V7O2peak were significant predictors of 7-8 year survival.  
Patients with a peak V7O2 <32.0 ml.kg
 -I min-I had an 8 year mortality rate of 
approximately 60%, whereas none of the children with a V7O2 peak >45 ml.kg
 -I min-I 
died in the follow up period.  The decline over time of FEV1 also predicted mortality.  A 
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decline in V7O2 peak ≥2.1 ml.kg
 -I min-I per year, or a decrease in FEV1 over a 5-year 
period was associated with an increased mortality rate.  Using a shorter follow up 
period of 5 year, Moorcroft et al., found that V7O2, FEV1% predicted and the ventilatory 
equivalent for O2 (V7E/V7O2) were better predictors of 5-year survival than V7O2 peak in 
92 CF patients [48].  
Changes in lung function may also impact on the decrease in V7O2peak observed 
in children with CF.  Klijn et al., [49] examined changes in nutritional status, lung 
function (FVC and FEV1) and V7O2 peak at baseline and in a 24-month follow-up in 65 CF 
children between the age of 4 and 18 years.  None of the participants had taken 
antibiotics in the previous 4 months.  Nutritional status was assessed by measuring 
height, weight and fat free mass (FFM).  Changes in lung function and, to a lesser 
extent, nutritional status were positively associated with changes in the aerobic 
capacity.  The change in FEV1 explained 38% of the variation in V7O2peak, and the 
combined change in FEV1 and FFM accounted for 47% of the variation in V7O2peak.   
Other Prognostic Indicators in CF 
FEV1 is commonly used to assess the mechanical properties of the large and 
medium-sized airways.  In apparently healthy individuals, the FEV1 accounts for the 
greatest part of the exhaled volume from a spirometric manoeuvre.  In a normal flow-
volume loop, the FEV1 occurs at approximately 75%-85% of the FVC, and is reduced in 
individuals with obstructive and restrictive lung disorders.  In obstructive pulmonary 
disease, FEV1 is reduced disproportionately to the FVC.  This reduces the FEV1/FVC 
ratio below the lower limit of normal indicates airflow limitation.  In restrictive 
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disorders, the FEV1, FVC, and total lung capacity (TLC) are all reduced, whereas the 
FEV1/FVC ratio is normal or even elevated.  The annual rate of decline in %pred FEV1 
across the CF population in the US is estimated to be 2% [14, 50].  Moorcroft et al., 
[51] found a decrease in FEV1 of 63.0 ml, or 2.4 % predicted per year in patients with 
mild to moderate disease.  Factors that may influence the rate of decline in FEV1% 
include nutritional status [52], diabetes, colonization with P. aeroginosa, frequency of 
pulmonary exacerbations [14, 53] and PI [49].   
Carbon dioxide (CO2) retention during exercise can also be used as a prognostic 
marker of disease progression in patients with mild to moderate CF [54].  Javadpour et 
al., [54] found the average decline in FEV1% per year for the CO2 retention group was 
4.9% compared with 2.3% for the non-CO2 retention group.  Preserving lung function is 
important considering that the mortality rate for patients with FEV1<30% predicted 
[55] is 50% within two years.  An FEV1<30% predicted is also a primary criteria for lung 
transplantation [56]. 
Colonisation with P. cepacia is associated with particularly poor prognosis.  The 
mortality rate is approximately 25% within one year of colonisation [55].  Poor 
nutritional status is also associated with reduced survival.  Sharma et al., [57] found 
that the 7-year prognosis was better in patients with a body weight >85% of ideal than 
in those with a body weight < 85% of ideal.  They suggested that muscle wasting is an 
excellent predictor of mortality independent of FEV1% predicted and arterial blood 
gases (PaCO2 and PaO2).  In contrast, Kerem et al., [55] found that % ideal body weight 
was not an independent predictor of survival [44].  The two-year mortality rate was 
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found to be 50% in patients with abnormal resting blood gases (PaO2 <55 mmHg and 
PaCO2> 50 mmHg) [54]. Patients with a “high risk” genotype CFTR mutation have a 
higher mortality rate than patients with a “low risk” genotype CFTR mutation [58]. 
Some CF patients remain relatively stable for a considerable period of time and 
then may have rapid lung disease progression.  Reduced FEV1, and a decline in FVC can 
be observed due to progressive lung scarring, air trapping and increased dead space 
(DS) ventilation [14].  
Physiological Response of the Healthy Respiratory System to Exercise 
Exercise intolerance is a primary characteristic of disease progression in CF, and 
is related to abnormal function of ventilatory, cardiovascular and peripheral muscles.  
Ventilatory limitation is a dominant contributor to exercise intolerance in more 
advanced CF disease.  The cardiorespiratory system maintains adequate O2 to the 
exercising muscle and removes CO2 during dynamic submaximal exercise in healthy 
individuals.  Despite O2 desaturation (<10% SvO2) and CO2 retention (PvCO2 >80 mm 
Hg) in mixed venous blood as V7O2 and V7CO2 reach maximum levels, the PO2 and PCO2  
in the blood leaving the lungs remains near resting levels in healthy individuals.    
A primary function of the respiratory system during exercise is to ensure 
normal gas exchange in order to maintain arterial PO2 and PCO2 close to resting levels.  
The time available for alveolar capillary diffusion at peak exercise is shortened due to a 
large increase in cardiac output.  However, pulmonary capillary pressure remains 
relatively constant due to a decrease in resistance.   
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Pulmonary ventilation can increase by twenty fold in order to supply O2 and 
remove CO2 from the working muscles during exercise.  PvCO2 increases from <50 
mmHg at rest to >80 mmHg at maximal exercise.  The excess CO2 must be eliminated 
in order to maintain arterial PCO2 and acid base status within the normal range.  The 
alveolar-arterial partial pressure difference (PA-aO2 diff) decreases and alveolar 
ventilation (V7A) and DC increases in order to maintain arterial PO2 at 100 mmHg.  In 
order to maintain arterial PO2 and PCO2 within the normal range,  ventilatory efficiency 
is increased by minimizing the increase in respiratory muscle work, pulmonary vascular 
pressure is maintained within normal limits, and DC is enhanced. 
Mechanics of Breathing during Exercise 
The work of breathing is the product of pressure and volume changes as shown 
in Figure  2.3.  The volume change refers to the difference in volume of air moved in 
and out of the lungs.  The pressure change is the change in transpulmonary pressure 
required to overcome both the elastic and resistive work of breathing.  The elastic 
work of breathing is the work performed to overcome the elastic recoil of the chest 
wall and parenchyma, and to overcome the surface tension of the alveoli [59].  The 
resistive work of breathing refers to the work undertaken to overcome the tissue and 
airway resistance.  Elastic work increases exponentially as tidal volume increases.  
When lung compliance decreases, additional force must be generated by the 
inspiratory muscles in order to expand the lungs. 
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Figure  2.3: Pressure-volume curve in the lungs at rest and during exercise 
The respiratory control centre functions to increase ventilation to maintain 
alveolar O2 and CO2 near the resting level while minimizing the mechanical work 
performed by the respiratory muscles [60].  Minimizing the metabolic cost of breathing 
will result in an increase in the volume of cardiac output that is available for delivery to 
other working muscles [61] and delay the onset of dyspnea [62].   
During exercise, the increase in V7A is proportional to the increase in metabolic 
rate.  An increase in tidal volume (VT) is primarily responsible for the increase in V7A 
during the transition from mild to moderate exercise.  This reduces the DS to tidal 
volume ratio (VD/VT), and minimizes the work of breathing, which is more related to 
respiratory frequency (RR).   
During exercise, the increase in VT is achieved by encroaching on both the 
inspiratory and expiratory lung volumes.  The balance between the inspiratory and 
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expiratory flow rate allows the lungs to reduce dynamic end expiratory lung volume 
(EELV) [63].  Progressive expiratory muscle recruitment ensures that VT is positioned 
on the linear portion of the respiratory system’s pressure volume loop (20 - 80% of 
vital capacity) where elastic loading is avoided (Figure  2.3), [63].  This allows VT to 
expand to a maximum of 55% of vital capacity (VC), by way of optimizing the length of 
the diaphragmatic and inspiratory intercostal muscles at the onset of inspiration.  As 
exercise progresses from moderate to higher intensity levels the VT plateaus and 
further increases in V7A are achieved by increasing RR (  Figure  2.4).  This 
reduces the time for inspiration (TI) and expiration (TE) [64].   
 
  Figure  2.4: Change in breathing pattern during exercise 
Control of Alveolar Ventilation: Defence of Alveolar PO2 and PCO2  
In healthy non-athletic individuals the capacity to increase flow rate and 
volume at rest is greater than at maximal exercise.  This increased resting ventilatory 
capacity represents a breathing reserve that is not utilized at maximal exercise due to 
cardiovascular limitations.  At maximal exercise, the respiratory muscles can achieve a 
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ventilation (V7E) level up to 180 L.min
-1 while using only 5%-7% of the total body V7O2 
[65].  This efficient breathing response is due to an increase in airway 
bronchodilatation and a decline in VD/VT.  Airway bronchodilatation occurs as a result 
of increased circulating levels of catecholamines.  At maximal exercise, VD/VT can 
decrease by approximately 30% of baseline value resulting in almost equal matching 
between V7E and V7A.  Dead space ventilation represents only 13% of total V7E at maximal 
exercise [66]. 
During low to moderate exercise, the precise regulation of alveolar ventilation 
relative to metabolic requirement is governed by a feedback signal from exercising 
muscle to the respiratory pattern generator in the medulla which drives ventilation, 
and a feed-forward mechanism from higher locomotor centres in the brain [67]. 
Above 75-80% of maximal exercise capacity, V7A increases out of proportion to 
CO2 production, resulting in a decrease in arterial PCO2.  The hyperventilatory response 
to heavy exercise results from stimulation of the carotid chemoreceptors via the 
metabolic acidosis pathway.  The hyperventilatory response helps to minimize the 
decrease in pH resulting from the accumulation of lactic acid (LA), and increases the 
alveolar PO2 and O2 pressure gradient to protect against the development of arterial 
hypoxemia.  This hyperventilatory response is an “extra” stimulus in addition to the 
input from the locomotor-linked feed-forward and feedback sources.  
Pulmonary Gas Exchange 
The efficiency of pulmonary gas exchange from the alveoli to the pulmonary 
capillary can be assessed by measuring the PA-aO2 diff.  The magnitude of the PA-aO2 diff 
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is determined primarily by the uniformity of V7A and pulmonary perfusion (Q).  Resting 
PA-aO2 diff averages 5 to 15 mmHg [68] in normal, healthy non-smoking young adults 
[69], and may raise another 5 to 10 mmHg by age 70 years.  The PA-aO2 diff begins to 
rise during mild exercise and can increase to 20 - 30 mmHg at maximal exercise in 
healthy untrained subject, ( Figure  2.5) [70].  The increase in PA-aO2 diff is due to a 
rise in PAO2, because V7A normally increases out of proportion to V7O2 and arterial PO2 is 
maintained near resting levels.  
 
 
 Figure  2.5: PA-aO2 diff and O2% saturation during progressive exercise to 
maximum in healthy young adult 
Potential mechanisms responsible for increasing the PA-aO2 diff include poorer 
mismatching of ventilation to perfusion (V7A/Q), and/or a reduction in the diffusion of 
oxygen from the alveoli to the pulmonary capillary.  With increasing exercise intensity 
V7A increases out of proportion to Q resulting in V7A/Q mismatching.  During heavy 
exercise, V7A/Q mismatching is 3 to 4 times higher than at the resting level.  An elevated 
alveolar PO2 is present across all V7A/Q units.  The increased O2 pressure gradient 
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between the alveoli and pulmonary capillary helps to maintain PaO2 at normal value 
despite the large reduction in mixed venous O2 content [70]. 
The second contributing factor to the increased PA-aO2 diff during exercise is the 
right to left shunt of mixed venous blood from the bronchial artery and the coronary 
vein that enters the arterial system without passing through the lung.  A 1-2% 
extrapulmonary shunt exists in normal lungs.  The third potential contributing factor is 
the failure of mixed venous blood in the pulmonary capillaries to equilibrate with 
alveolar O2 pressure.  Disequilibrium may occur if the time required for the 
equilibration is greater than the time that red blood cells (RBC) spend in the gas 
exchange unit.  The average time that a RBC remains in the pulmonary capillary is 
known as the transit time and is approximately 0.75 seconds at rest.  However, only 
0.3 seconds is required for the RBC to equilibrate with alveolar PO2.  Although the 
transit time may decrease to 0.4 seconds during high intensity exercise, it is still 
efficient to complete oxygenation of haemoglobin [71] in a normal alveolar capillary 
membrane.  
The increase in PA-aO2 diff in healthy men and women may be  due to V7A/Q 
mismatching and a small anatomical shunt of mixed venous blood.  However, a 
significant decrease (3-13%) in SPO2 has been shown to occur during maximal exercise 
at sea level in healthy elite athletes [69].  These findings provide evidence that the 
even in healthy individual the respiratory system may not always be able to maintain 
normal gas exchange.   
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The lungs have a number of mechanisms that help to minimize the widening of 
the PA-aO2 diff and enhance DC.  Firstly, the alveolar capillary diffusion surface can be 
increased by the recruitment of additional pulmonary capillaries.  Secondly, the 
pulmonary arterioles have a thin flexible wall that helps to maintain a low pulmonary 
vascular resistance and minimize the increase in pulmonary capillary pressure [72].  
Thirdly, pulmonary capillary volume expands up to 3 fold in response to the increase in 
pulmonary blood flow.  This helps to minimize the reduction in transit time.  
Ventilatory Response at Rest in CF 
CF is a disease characterized by dysfunction of both the small airways (<2 mm) 
and large airways.  Disease progression is associated with parenchyma destruction 
secondary to bronchietasis [75].  Progressive structural lung damage eventually leads 
to end stage lung disease accompanied by a severe reduction in pulmonary diffusion.  
Children with CF have evidence of early small airway damage due to inflammation [73].  
This process is irreversible and may also be found in children with CF with a normal 
pulmonary function.  
Increased severity of CF is associated with destruction of the parenchyma, 
resulting in a reduced lung compliance [76].  An increase in resting respiratory muscle 
load is found in severe CF patients due to a decrease in lung compliance.  Patients with 
severe CF tend to take small rapid breaths in order to help minimize the increase in 
elastic force of inspiration and to compensate for the reduction in FEV1 [76].  However, 
rapid shallow breathing may increase VD/VT resulting in alveolar hypoventilation, 
hypoxemia and hypercapnia (increased arterial CO2) [77].   
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As CF becomes more advanced, the disease may become a heterogeneous 
disorder characterized by dysfunction of the small and large airways and by 
parenchyma and vascular destruction, in highly variable combinations.  Although the 
most obvious physiological defect in CF is expiratory flow limitation, Hart et al., [76] 
found that elastic forces have more effect on ventilatory mechanical constraint than 
the resistive forces during resting breathing in severe CF patients.   
Pulmonary hyperinflation may affect the ventilatory response at rest in children 
with CF [78].  Pulmonary hyperinflation is present when an expiratory flow limitation 
reaches a critical level and EELV fails to decline below functional residual capacity 
(FRC).  Pulmonary hyperinflation increases both the work of breathing and the 
sensation of breathlessness, and impairs respiratory muscle function [79-81].  The 
reduction in lung compliance and lung hyperinflation decreases resting VT in advanced 
CF [78].  However, a recent study found that the presence of static hyperinflation 
(%RV/TLC) in adolescents with mild to moderate CF did not strongly influence 
ventilatory constraints during exercise.  The static hyperinflation was only a slightly 
stronger predictor of peak exercise capacity than FEV1%. [82].  
Ventilatory Mechanics and Exercise Intolerance in CF Patients 
Pulmonary hyperinflation along with a reduction in resting lung compliance 
may affect exercise performance in CF patients.  During exercise, dynamic pulmonary 
hyperinflation (DH) is present when EELV is increased above the resting value [6].  
Regnis et al., found DH in CF patients with FEV1 <60% resulted from a combination of 
flow limitation and an increased ventilatory demand [6-7].  When DH is present, VT is 
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positioned close to the TLC on the steep portion of the pressure volume loop resulting 
in a higher pressure being required to increase VT for any given volume expansion.  
During exercise VT can increase up to 90% of the end inspiratory lung volume (EILV) 
where further volume expansion is minimal.  At a fixed VT, moderate to severe CF 
patients rely on increasing RR in order to increase V7E [6-7].  DH progressively increases 
with CF severity due to an increase in airway obstruction.  In patients with severe CF, 
DH may be present during low intensity exercise.   
DH may also increase inspiratory muscle loading [83].  Since inspiration begins 
at higher lung volumes in patients with moderate to severe CF than in healthy 
individuals, inspiratory muscles must counterbalance the combined inward recoil of 
the lung and chest wall prior to the initiation of inspiratory flow [6-7].  Higher tidal 
inspiratory pressures and effort must be generated for any given VT expansion 
resulting in an increase in the mechanical work and O2 cost of breathing.   
DH can alter the length-tension relation of the inspiratory muscles, particularly 
the diaphragm, and compromise their ability to generate pressure [84].  Resting 
maximal diaphragm strength is reduced by 20% in severe CF patients due to muscle 
shortening secondary to hyperinflation [84].  Rapid shallow breathing (tachypnea) is 
also associated with respiratory muscle shortening during exercise resulting in further 
inspiratory muscle weakness [85].  The combined overloading and reduced maximal 
strength of the inspiratory muscles leads to premature inspiratory muscle fatigue 
during exercise in moderate to severe CF patients [81] .  
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Gas Exchange Abnormality at Rest in CF Patients 
Studies that have evaluated gas exchange at rest in patients with CF have been 
equivocal.  An early study found that resting V7A/Q ratio is decreased in hypoxemic 
moderate CF patients, indicating that the alveolar shunt is the primary mechanism 
responsible for hypoxemia in these patients [86].  It is possible that unventilated 
alveoli beyond the obstructed small bronchioles (interpulmonary shunt) may be 
responsible for the impaired gas exchange.  In contrast, other investigators found that 
resting V7A/Q ratio is increased in moderate to severe CF patients due to a local 
hypoperfusion caused by hyperinflation [33, 87].   
Gas Exchange Abnormality and Exercise Intolerance in CF Patients 
In patients with airway disease, an increased PA-aO2 diff during exercise typically 
results from hypoventilation of lung regions relative to their perfusion.  Abnormal gas 
exchange may result in arterial hypoxemia which may limit exercise performance in CF 
patients with moderate to severe lung disease.  CF patients with a severe reduction in 
resting carbon monoxide diffusion capacity (DLCO <80% of predicted) are more likely to 
develop arterial hypoxemia at peak exercise [88].  The severity of arterial hypoxemia 
during exercise cannot be predicted from resting spirometry [89].  The mechanisms 
responsible for exercise hypoxemia in CF are not well understood and may be due to 
ventilation/perfusion mismatching [87-88], intrapulmonary shunting, and alveolar 
hypoventilation [89].   
The ventilatory equivalent for O2 (V7E/V7O2) and CO2 (V7E/V7CO2) and the VD/VT 
ratio can be used to indicate the ventilatory demand at a given metabolic rate and 
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therefore provide additional information on ventilatory efficiency.  The V7E/V7O2 and 
V7E/V7CO2 are dependent on a number of factors that link ventilation to metabolic 
regulation.  An abnormally elevated ventilatory equivalent in the presence of a high 
PaCO2 may indicate poor distribution of ventilation, areas of the lung with high V7A/Q or 
an increase in DS.  The measure of V7E/V7CO2 at the anaerobic threshold (AT) can be 
clinicaly very usefull.  The minimal V7E/V7CO2 is about 25 in healthy young subjects.  
However, it exceed 30 in older individuals.  A V7E/V7CO2 value < 32-34 at or near the AT 
and <36 at peak exercise in normally found in healthy individuals.  Furthermore, the 
V7E/V7CO2 at the AT is similar to the lowest V7E/V7CO2 ratio when the AT can not be 
determined during an exercise test [90].  
An elevated VD/VT ratio is a better predictor of an intrinsic lung abnormality 
than the ventilatory equivalents.  Patients with moderate to severe CF have been 
shown to have an elevated VD/VT at peak exercise due to a low VT and an increased RR 
[91].  An elevated VD/VT will result in a greater proportion of each breath moving in and 
out of the airway DS causing arterial hypoxemia.  
Role of the Respiratory System in Limiting Exercise Performance in CF 
It is not known whether peak exercise capacity is limited by pulmonary 
mechanisms or gas exchange in moderate to severe CF.  McKone et al., [4] compared 
the effect of adding DS alone, and the combination of DS with supplemental O2, on 
peak exercise responses in patients with moderate to severe CF.  The increased DS 
reduced peak exercise capacity with no change in peak V7E, suggesting a respiratory 
limitation to exercise.  In contrast, peak exercise capacity and peak V7E increased when 
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supplemental O2 was provided in the presence of added DS, suggesting that hypoxemia 
rather than pulmonary mechanics are responsible for limiting peak exercise capacity in 
moderate to severe CF.  
In order to stress the ventilatory system, Dodd et al., [92] provided additional 
DS to the respiratory system during a graded exercise test in patients with mild CF.  
Peak V7E increased through increases in VT because the participants had an adequate 
ventilatory reserve to overcome the additional DS.  These findings suggest that 
ventilatory mechanics are not a limiting factor during peak exercise in patients with 
mild CF.  In contrast, Keochkerian et al., [93] found that children with mild to moderate 
CF developed an expiratory flow limitation during transition from light exercise 
intensity to peak exercise.  These findings suggest that ventilatory mechanics due to 
DH may be a limiting factor during submaximal exercise and during peak exercise in 
patients with mild to moderate CF.  
Cardiovascular Factors in CF 
The effect of CF on cardiac response during exercise is complex and involves 
many factors.  In chronic obstructive pulmonary disease (COPD), severe lung 
hyperinflation and excessive expiratory muscle recruitment can impair venous return 
and reduce right ventricular (RV) preload.  Several studies have demonstrated an 
increase in pulmonary vascular resistance during exercise in COPD [94-95] resulting 
from a reduction in the area of the pulmonary vascular beds, a decrease in compliance, 
and hypoxemia [96].  
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The morphological pulmonary vascular changes in CF are similar to that of 
other hypoxic lung diseases [97].  Ryland et al., [98] studied the heart and lungs of 36 
CF children.  All patients had some degree of pulmonary artery muscle hypertrophy, 
arterial sub-intimal fibrosis and thickening of the pulmonary vein wall.  The thickness 
of the muscular wall was significantly related to the degree of RV hypertrophy.  
A number of studies indicate that pulmonary hypertension (PH) and RV 
enlargement occurs in CF patients due to pulmonary vascular remodelling [99-100].  
The incidence appears to be higher in patients with severe CF disease.  The prevalence 
of clinical RV disease in CF is unknown, but prognosis is poor once RV failure is evident 
[101].  
Cardiovascular Response during Exercise in CF 
Stroke volume (SV) during exercise in affected by CFseverity  [102-103].  Radio 
angiography studies have demonstrated that both RV and left ventricular (LV) ejection 
fraction may be decreased during exercise in CF.  Hortop et al., [104] found a relation 
between expiratory flow limitation and cardiac performance during exercise in 
patients with moderate CF disease.  It was speculated [104] that the expiratory flow 
limitation may increase expiratory muscle action resulting in an increase in abdominal 
and intrathoracic pressure throughout expiration.  This may compromise cardiac 
output (CO) by reducing the venous return and by increasing pulmonary vascular 
resistance. 
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Cardiovascular Basis of Exercise Gas Exchange 
Measuring respiratory gas exchange (V7O2 and V7CO2) is particularly relevant for 
evaluating the cardiovascular response during exercise.  Oxygen uptake during exercise 
is a product of CO and the arterial-venous O2 difference [c(a-v)O2].  Cardiac output 
increases during exercise due to an increase in both heart rate (HR) and SV.  Widening 
c(a-v)O2 depends on the extraction of O2 from the capillary blood in the exercising 
muscle, and the distribution of blood flow to the muscle.  In the absence of significant 
anaemia or hypoxemia, maximal c(a-v)O2 differs very little between healthy and 
diseased persons [105]. 
V9O/Heart Rate Relationship (Oxygen Pulse) 
The volume of O2 extracted during each heartbeat is called the oxygen pulse (O2 
pulse) and is equal to the product of SV and c(a-v)O2 .  Due to the fact that c(a-v)O2 at 
peak exercise does not vary widely between healthy subjects and CF patients with 
normal RCB and Hb values, the between-subjects variability in O2 pulse at peak 
exercise is determined largely by differences in SV [105].  If the O2 pulse reaches a 
plateau despite an increase in work rate (WR), it most frequently reflects a low 
maximal SV [105].  Central factors, particularly those that effect SV including heart 
disease, deconditioning, ventilatory limitation, and possibly even the hemodynamic 
consequence of dynamic hyperinflation may decrease O2 pulse.  Factors that effect  
c(a-v)O2 including abnormal O2 utilization, desaturation and anaemia may also reduce 
the O2 pulse.  Consequently, caution should be taken when interpreting changes in O2 
pulse response as a function of SV when patients are hypoxemic.  
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HR- V9O2 Relationship 
Among normal subjects, HR increases almost linearly with V7O2, and reaches a 
maximal value.  In many types of heart disease, the HR increase is relatively steep for a 
given increase in V7O2 due to left ventricular dysfunction.  Patients with airflow 
obstruction commonly have a moderately elevated HR at a given V7O2 due to a reduced 
SV [106].  The reduction in SV in these patients results from a restriction in cardiac 
filling due to high intrathoracic pressure during exhalation.  Pulmonary vascular 
disease is also associated with a steep HR response due to pulmonary hypertension 
(PH).  PH may increase the work of the RV and reduce SV [106]. 
VO2 in Relation to Work Rate (∆VO2/∆WR) 
Normally V7O2 increases linearly with increasing external WR during a 
progressive cycle exercise test.  The slope of the relation between V7O2 and WR is 
influenced by the change in WR relative to the subject’s capacity, but is approximately 
8.5-11 ml.min-1.watt-1 over the entire range of V7O2 from unloading cycling through 
peak exercise.  A decrease in the normal relation between V7O2 and WR implies an 
abnormal reliance on non-oxidative metabolism.  Because the metabolic efficiency of 
exercising muscles is relatively constant, a reduction in ∆V7O2/∆WR usually indicates 
inadequate O2 transport, as may occur in individuals with cardiovascular disease or 
COPD..  However, muscle-related abnormality in O2 metabolism has been reported in 
children with mild to moderate CF [10]. 
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Peripheral Muscle Dysfunction and Exercise Intolerance in CF 
Muscle dysfunction may contribute to the reduced exercise tolerance observed 
in CF patients [36, 84, 106-113] and may be due in part to reduced activity levels or 
immobility due to dyspnea [107].  Muscle dysfunction in CF may include [107-109] 
muscle weakness [110], decreased number of mitochondria [8, 10, 110-111], and 
increased reliance on anaerobic glycolysis [8, 111].   
Effect of Deconditioning in Normal Skeletal Muscle  
Deconditioning is a term used to describe the physiological effects of decreased 
activity.  The physiological effect of immobilisation on peripheral muscle is 
characterised by  atrophy, fibre type re-distribution, altered bioenergetics, and altered 
capillarization.  Atrophy is the process whereby muscle size is reduced, almost 
exclusively because of reductions in the contractile proteins, actins and myosin.  
Skeletal muscle mass is normally maintained by a balance between protein synthesis 
and protein degradation.  The signalling pathways that govern muscle atrophy are not 
fully defined.  Nuclear factor kB (NF-kB) is a central regulator involved in the regulation 
of both the atrophy and hypertrophy signalling pathways [112].  It is down-regulated 
during muscle atrophy.  In general, atrophy is reversible and affects both type I and 
type II fibres.  
Muscle type redistribution represents a change within type II fibres.  Type IIa 
fibres may take on the physiological and biochemical characteristics of type IIb fibres 
that have less oxidative and more glycolytic potential.  There is also evidence that long-
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term inactivity and/or chronic disease can alsoresult in a shift between type I to type II 
fibre type characteristics [113].    
In healthy individuals, deconditioning is associated with a reduction in the 
concentrations of enzyme markers of aerobic oxidative capacity.  In contrast, there 
appears to be no change in the concentration of enzymes involved in anaerobic 
glycolysis.  Deconditioning is also associated with a reduction in the total mitochondrial 
content and capillary density.  Both of these changes may have a negative impact on 
muscle endurance [114].  
Muscle Dysfunction in CF 
Moorcroft et al., [115] compared ratings of muscle effort and breathlessness, 
blood lactate levels and exercise limitation at peak cycle exercise in adults with mild, 
moderate and severe CF and healthy controls.  Ratings of muscle effort were higher 
than ratings of breathlessness at peak exercise in all patient groups than healthy 
controls.  Although peak work rate was higher in the healthy controls than in the CF 
patients, there was no difference in peak lactate between the two groups.   
Some studies have found evidence of intrinsic abnormality in muscle function 
in CF independent of deconditioning [8, 10].  Compared to healthy individuals, CF 
athletes with good nutritional status and a preserved pulmonary function have lower 
anaerobic power and maximal leg strength, and a reduced mitochondrial oxidative 
metabolism [8].  Abnormal expression of CFTR in skeletal muscle may be responsible 
for the reduction in oxidative and anaerobic metabolism due in part to ATPase 
hydrolysis by CFTR proteins [116].  Other factors that may contribute to peripheral 
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muscle weakness include malnutrition, systemic inflammation [117], medication 
(especially corticosteroid) [118], hypoxia, and oxidative stress [119] 
Prolonged nutritional depletion is associated with a reduction in muscle mass 
[120].  The effect of nutritional depletion is greater in type II than type I muscle fibres.  
Greater atrophy of type II fibres ensures that the tension of the muscle generated 
during daily activity is preserved.  However, maximal strength and endurance may be 
impaired [121].  Poor nutritional status may limit exercise capacity in CF patients.  In 
patients with severe airway obstruction, Boucher et al., [122] found that physical 
activity levels were related to nutritional status but not to lung function.  Similarly, 
nutritional status has been identified as a major determinant of anaerobic exercise 
capacity in CF patients due in part to atrophy of type II fibres [108].  
Systemic inflammation may contribute to muscle atrophy in respiratory and 
non-respiratory chronic diseases.  In CF, systemic inflammation is more prolonged than 
other chronic disease due to endobronchial inflammatory process of the affected 
lungs.  Cell culture models found that pro-inflammatory cytokines, such as TNF-α, 
induced protein breakdown through activation of NF-kB via an increased production of 
mitochondrial reactive oxygen species [123-124].  Defrense et al., [117] found a 
relation between the severity of lung disease in mild to moderate CF and inflammatory 
cytokines including IL-6 and TNF-α.  However, there was no relation between 
inflammatory cytokines and lean body mass and muscle strength of the diaphragm, 
biceps and quadriceps.  
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Steroid-induced myopathy, particularly in type IIb muscle fibres is associated 
with prolonged use of oral corticosteroids.  Recovery following chronic steroid 
myopathy may take many weeks to months [125].  Chronic steroid use may affect the 
synthesis of contractile proteins and the turnover of biochemical substrates in skeletal 
muscles.  Corticosteroid may downregulate insulin-like growth factor 1 (IGF-1), and 
thus may decrease protein synthesis and increase intracellular proteolysis.  Daily use of 
5.1 mg.day-1 of corticosteroid over 12 months has been shown to reduce maximal limb 
muscle strength in CF patients.  The results were independent of the severity of airway 
obstruction, nutrition and days spent in hospital during the previous 12 months [118].  
Chronic or intermittent hypoxia is common in moderate to severe CF patients.  
In healthy humans, exposure to high altitude hypoxia over weeks and months results in 
functional, morphological and metabolic changes in the skeletal muscle [126].  Tissue 
hypoxia limits the production of energy and affects protein synthesis, leading to 
muscle loss, increased glycolytic activity and reduced oxidative enzyme activity [127].    
Hypoxemia can also trigger other pathogenetic mechanisms related to muscle 
dysfunction, such us an increase in the levels of circulating cytokines and oxidative 
stress [128].   
An imbalance between oxidant and antioxidant capacity of the cells can lead to 
oxidative damage of protein, lipids, and nucleic acid, a process known as oxidative 
stress.  Oxidative stress can alter muscle contractility, potentially affecting muscle 
strength, and may contribute to muscle fatigue [119].  Oxidative stress can also 
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contribute to accelerated protein degradation [129].  Antioxidant supplementation has 
been shown to improve exercise tolerance in COPD patients [130].   
O2 Uptake Kinetics  
O2 Uptake Kinetics during Constant Load Exercise 
The rate of adjustment of oxidative phosphorylation to sudden increases in 
energy demand has been termed O2 uptake kinetics.  It reflects the integrated 
response of the ventilatory, cardiovascular, and neuromuscular system to the exercise 
challenge [131].  The pattern for the increase in pulmonary V7O2 at the onset of a 
constant load exercise can be described by the monoexponential function [132].  Three 
phases are normally considered.  Phase I (time delay (TD)) represents the 
cardiodynamic phase and reflects the increase in pulmonary blood flow without an 
increase in arteriovenous O2 difference.  It is approximately 15-20 seconds in duration 
and reflects the time period prior to the blood from exercising muscles entering the 
pulmonary capillary [133].  Phase II represents the adjustment of the metabolic 
response to exercise [133].  It reflects the arrival at the lungs of the mixed venous 
blood and lasts from approximately 15-20 seconds after the onset of exercise to the 
third minute of exercise [133].  Phase III begins at approximately 3 minutes after the 
onset of exercise, and reflects the start of the V7O2 steady state period when the work 
rate is below the AT.  However, if the exercise intensity is above the AT, V7O2 steady 
state is delayed or not achieved prior to fatigue (V7O2 slow component) [134].   
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Modelling O2 Uptake Kinetics during Moderate and Heavy Exercise 
O2 uptake kinetics are modelled using non-linear least-square regression 
techniques.  The V7O2 response data is fitted to a mono-exponential function that 
includes a single amplitude and time constant (τ) [133].  The mean response time 
(MRT) indicates the time taken for O2 to reach 63% of the response amplitude from 
the onset of exercise with no distinction made for the cardiodynamic phase (phase I) 
[135].  The normal value for MRT in healthy individuals is approximately 30-40 seconds 
[136].  
The monoexponential fit of the V7O2 response in phase I and phase II can be 
described using the following equation:  
O2 (t) = O2 baseline + (A) x (1-e-t/τ) 
Where O2 (t) represents the absolute O2 at a given time t; O2 baseline represents the 
mean O2 in the baseline period preceding the step transition to the higher work rate;  
A represents the response V7O2 steady state amplitude; (1-e-t/τ) is the exponential 
function describing the rate at which V7O2 is rising towards the steady state amplitude; 
t is the time and τ represents the MRT, as shown in  Figure  2.6.  
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 Figure  2.6: Overall VO2 kinetics expressed as MRT to attain 63% of overall 
response 
Oxygen Deficit 
The fact that O2 uptake kinetics do not increase instantly to a level that meets 
the V7O2 demand of submaximal exercise below the AT indicates that an anaerobic 
energy contribution makes up the difference.  The difference between the amount of 
energy contributed from aerobic ATP production and that required to sustain exercise 
is called the oxygen deficit (O2D).  The energy provided during the deficit phase of 
exercise represents a predominance of anaerobic energy transfer.  These stores consist 
principally of energy released through phosphocreatine (PCr) hydrolysis and anaerobic 
glycolysis [76].   
The absolute size of the O2D is the product of the increase in V7O2 amplitude (A) 
and the MRT, from the onset of exercise (O2D = A x MRT) ( Figure  2.7).  For a given 
∆V7O2, the faster the O2 uptake kinetics (smaller MRT), the smaller the O2D.  Sedentary 
individuals or patients with chronic cardiovascular and pulmonary disease have a slow 
O2 uptake kinetics (large MRT) and high O2D.  A larger MRT is associated with a greater 
anaerobic contribution to the energy requirement resulting in a greater accumulation 
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of lactic acid in the exercising muscle.  The increase in lactic acid concentration 
contributes to exercise intolerance [99]. 
 
 Figure  2.7: O2 deficit as a function V̇O2 amplitude and MRT 
O2 Uptake Kinetics during Moderate Exercise in Healthy Individuals  
The kinetics of the V7O2 adjustment to a new metabolic requirement is reflected 
by the capacity of the O2 delivery to muscle fibres, and the intracellular oxidative 
metabolism within the muscle fibres [136-137].  In healthy young individuals, O2 
delivery is adequate to support the metabolic requirement in the transition from rest 
to moderate exercise.  The rate of increase in V7O2 to its asymptote is determined by 
metabolism within the muscle fibres [131] and is related to enzyme activation and/or 
concentrations of cellular metabolic controllers.  
O2 Uptake Kinetics during Heavy Exercise in Healthy Individuals  
O2 uptake kinetics during heavy exercise is determined by the magnitude of 
both the primary component and the V7O2 slow component [138].  In healthy 
individuals, the primary component lasts 2 -3 minutes following the onset of exercise 
and is dependent on the percentage of type 1 oxidative fibres within the exercising 
muscle.  A higher proportion of type 1 fibres may accelerate the primary component 
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kinetics.  The magnitude of the V7O2 slow component has been described as the 
difference between V7O2 at 2 minutes and 6 minutes (∆V7O2 6-2min) [139-140] or V7O2 at 
3 minutes at the end of the exercise as shown in Figure  2.8 [139].  Putative 
mechanisms responsible for the V7O2 slow component during heavy exercise include i) 
increased cardiac and respiratory muscle work, ii) increased O2 cost of lactate 
catabolism [138] and gluconeogenesis [155-156], iii) increased activity/recruitment of 
IIX fast twitch glycolytic fibres within the skeletal muscle and iv) the pattern of motor 
unit recruitment [141-142].  The delivery of O2 to exercising muscle may play a role in 
limiting O2 uptake kinetics during heavy exercise  [143].  Providing supplemental O2 
during heavy constant load exercise accelerates O2 uptake kinetics in healthy 
individuals [144].  
 
Figure  2.8: V̇O2 slow amplitude during moderate (A) and heavy (B) constant WR 
exercise for healthy adults 
O2 Uptake Kinetics during Moderate and Heavy Exercise in Pulmonary Disease  
O2 uptake kinetics is slower than normal in chronic diseases such as COPD 
[145], CF [146], heart failure [147-149], peripheral vascular disease [147], and type II 
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diabetes [139].  In individuals with COPD, O2 delivery to exercising muscle is the 
primary limitation for O2 uptake kinetics.  Providing supplemental O2 during moderate 
exercise accelerates O2 uptake kinetics and reduces the O2 deficit in hypoxemic COPD 
[150], but has no effect on non-hypoxemic COPD [151].  
Relatively few studies have examined O2 uptake kinetics in CF.  The results were 
equivocal.  Hebestreit et al., [146] found that O2 uptake kinetics was slower during 
moderate exercise in mild to moderate CF patients than in healthy controls.  The 
slower O2 uptake kinetics was related to a reduction in O2 delivery to the exercising 
muscle.  In contrast, providing supplemental O2 has been shown to have no effect on 
O2 uptake kinetics in mild to moderate CF during moderate exercise [152].  
Compared to healthy individuals, O2 uptake kinetics during heavy exercise may 
be slower in patients with COPD due to a reduction in systemic and peripheral O2 
delivery to the exercising muscle.  Factors responsible for the reduction in oxygen 
delivery include a higher ventilatory demand, abnormal breathing pattern [153], 
hypoxemia [150] and an abnormal peripheral vascular response [154].   
An impaired pulmonary hemodynamic response may also play a role in the 
slower V7O2 kinetics during heavy exercise in COPD patients [155].  A high mean 
intrathoracic pressure due to increased resistive and elastic loading of the respiratory 
muscles could dynamically impair the rate of right ventricular filling and left ventricular 
emptying.  The alteration in ventricular function may lead to a reduction in peripheral 
muscle O2 delivery and may impair O2 uptake kinetics [144].  Providing bronchodilator 
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therapy before heavy exercise reduces lung hyperinflation and accelerates O2 uptake 
kinetics in patients with moderate to severe COPD [155].  
Exercise Training  
As the severity of CF progresses, breathlessness and exercise intolerance are 
more prevalent.  Pulmonary V7E and RR consistently account for the greatest amount of 
variation in rating of perceived exertion during treadmill and cycle ergometer 
exercise[156].  Indeed, adjustments in respiratory rate during dynamic exercise appear 
to be one of the primary physiological mediators of respiratory metabolic signals of 
perceived exertion.   
An individual’s preferred level of intensity of physical activity depends in part 
on his or her affective response (pleasure or displeasure) resulting from sensory 
experience from various parts of the body.  When given a choice, individuals will 
generally adjust their effort intensity during exercise to maximize affect (short 
duration, high intensity emotion or feeling).  The short term rewards of positive 
affective responses that can be derived from a positive exercise experience might 
assist people to stay motivated to sustain regular physical activity and avoid drop out.  
Increased breathlessness at relatively low to moderate levels of physical activity may 
lead to a reduction in affect during exercise and decrease compliance.  As the disease 
becomes more advanced, patients with CF may spend less time undertaking activities 
of daily living resulting in peripheral muscle wasting.   
Inactivity in healthy individuals has been shown to negatively impact on muscle 
structure and function [157].  There is accumulating evidence that exercise intolerance 
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in patients with CF is also associated with abnormalities in skeletal muscle.  It is not 
clear whether the abnormalities are related to deconditioning or to abnormal intrinsic 
muscle function.  Exercise training has the potential to preserve muscle mass, improve 
exercise capacity and restore patients to the highest level of independent function.     
The majority of published studies of exercise training in CF have been short 
term, involved small numbers of subjects and have not included a control group.  In a 
recent review involving 26 studies, Wilkes et al., [158] examined the effects of 
prescribed exercise training in addition to medical management in CF.  Only 7 of the 
studies that used a randomized controlled design were included in the analysis.  There 
was evidence of an improvement in exercise capacity and muscle strength but the 
results were not consistent between studies [11, 156, 159-166].  Shah et al., [108] 
found that exercise training had no effect on gas exchange, and has only a minor effect 
on resting pulmonary function in CF. 
Moorcroft et al., [106] examined the effects of a one year unsupervised home-
based exercise programme in 48 adults with CF.  Subjects were randomly assigned to a 
control group or an exercise group.  Heart rate and pulmonary function were also 
assessed at the beginning and end of the training programme.  Blood lactate levels 
were measured at the end of a submaximal arm and leg ergometry test to assess 
improvement in fitness.  The exercise group received personalized training 
programmes based on their exercise preferences with the aim of increasing their levels 
of physical activity.  Lower and whole body exercises were focused on aerobic training, 
and the primary upper body exercise was weight training.  Subjects undertook three, 
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20 minute sessions of upper body and three sessions of lower body exercises per 
week.  In addition to keeping a training diary the subjects also met with an exercise 
specialist every 4 weeks.  FEV1 in the exercise, and control group declined by 67 ml and 
174 ml, respectively.  The one year decline in FEV1 in the exercise group (1.5%) was 
lower than predicted (2-3 %) [11].  FVC improved by 46 ml in the exercise group and 
decreased by 167 ml in the control group.  Blood levels of lactic acid and heart rates 
were significantly lower in the exercise group than in the control group during the 
constant load submaximal leg ergometry test.  There was no change in lactate 
concentrations and heart rates during the arm ergometer test.  Orenstein et al., [164] 
also found n increase in muscle strength and physical capacity in response to a 12-
month home-based resistance and aerobic training programme.  
Specific Strategies to Overcome Ventilatory Limitation in CF   
The challenge in the design of a training programme is to stimulate the 
cardiovascular system and the musculoskeletal system in order to induce positive 
adaptive changes [167].  Exercise training programmes should be adapted and 
designed to the patient’s limitation, taking pulmonary and skeletal muscle limitations 
into account.  It is recommended that healthy individuals should exercise 3 to 5 days a 
week at an intensity between 40 to 75% of peak exercise capacity [168-169].  The 
majority of patients with mild CF can exercise at these recommended intensities.  
However, these training intensities may not be tolerated by patients with moderate to 
severe CF due to the central ventilatory limitation.   
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Interventions that permit a higher level of ventilation, or reduces the 
ventilatory requirement at a given level of exercise, may allow CF patients to perform 
training at a higher intensity [4, 12].  This may lead to enhanced training benefits 
particularly in moderate to severe patients with FEV1 <60% predicted.  Supplemental 
O2 has recently been shown to improve maximal and submaximal exercise endurance 
in CF patients [4].  The mechanisms responsible for the improvements in exercise 
performance are not fully understood.  It appears that the provision of supplemental 
O2 may reduce ventilatory demands and therefore delay the time before reaching 
ventilatory limitation.  A number of mechanisms may help to explain how 
supplemental O2 reduces the ventilatory response during acute exercise in patients 
with pulmonary disease.  Firstly, supplemental O2 may diminish hypoxic drive from 
peripheral chemoreceptors due to an increase in PaO2 resulting in a decrease in 
respiratory rate [151].  Secondly, the reduced metabolic acidosis as a result of 
improved O2 delivery to the active muscles may decrease carotid body stimulation 
[170].    
Summary 
There is increasing evidence that the exercise intolerance associated with 
progression of CF severity reflects an integrated abnormality of ventilatory and 
peripheral muscles.  Understanding the complex interface between physiological 
impairment and disability is important in order to improve our understanding of the 
role of exercise in the treatment of CF.  Exercise training may partly reverse the 
cardiovascular abnormalities associated with CF.  Furthermore, the provision of 
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supplemental O2 may potentiate the training effect, and improve exercise tolerance in 
CF patients.  
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Chapter 3  
  Study 1  
Breathing Pattern, Pulmonary Gas Exchange, and Cardiovascular Responses during 
Incremental Exercise in Adults with Cystic Fibrosis 
Introduction 
Exercise intolerance is well documented in patients with CF [8, 10, 109-110, 
115].  Peak exercise capacity in these patients is limited by a number of factors, 
including impaired respiratory system mechanics [5-7], arterial hypoxemia [4, 88-89], 
peripheral skeletal muscle dysfunction [106-108, 112], and cardiovascular factors [102-
103].  However, the effect of CF on cardiac performance during exercise has received 
little attention. 
It is not known whether peak exercise capacity in moderate to severe CF is 
limited by pulmonary mechanisms or arterial hypoxemia.  Gallagher et al., [4] 
compared the effect of adding DS alone, or in combination with supplemental O2, on 
peak exercise response in patients with moderate to severe CF.  The addition of DS 
volume reduced peak exercise capacity with no change in peak V7E, suggesting a 
respiratory limitation to exercise.  In contrast, peak exercise capacity and peak V7E were 
increased when supplemental O2 was provided in the presence of added DS, suggesting 
that hypoxemia rather than pulmonary mechanics are responsible for limiting peak 
exercise capacity in moderate to severe CF.  
An important determinant of inspiratory muscle length and airway calibre is 
EELV.  An increase in EELV affects both mechanical breathing efficiency and the 
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distribution of inspired flow.  DH is present when an expiratory flow limitation (EFL) 
reaches a critical level during exercise, and end expiratory lung volume fails to decline 
below the relaxation FRC [6].  DH increases both the work of breathing and the 
sensation of breathlessness, impairs respiratory muscle function and decreases 
exercise capacity [79-81].  An increase in EELV resulting from a combination of EFL and 
an increased ventilatory demand has been found at peak exercise in CF patients with 
FEV1 <60% predicted [5, 171].  DH during exercise may limit VT and exercise capacity in 
CF patients with FEV1 < 60% of predicted [5-6].  
Dodd et al., [92] provided additional DS during a graded exercise test in 
patients with mild CF.  Peak V7E increased due to the fact that participants had an 
adequate ventilatory reserve to overcome the additional DS.  These findings suggest 
that ventilatory mechanics are not a limiting factor at peak exercise in patients with 
mild CF.  In contrast, ventilatory mechanics due to DH may be a limiting factor during 
submaximal exercise and at peak exercise in children with mild to moderate CF[ 93].    
Alterations in peripheral muscle function may also limit exercise performance 
in CF [106-108].  Moorcroft et al., [115] compared ratings of muscle effort and 
breathlessness and blood lactate levels at peak cycle exercise in adults with mild, 
moderate and severe CF and healthy controls.  Ratings of muscle effort were higher 
than ratings of breathlessness at peak exercise in patients with mild to moderate CF 
but were similar in the severe CF group.  Although peak work rate was higher in the 
healthy controls than the CF patients, there was no difference in peak lactate between 
the two groups.   
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The effect of CF on cardiac performance during exercise is complex and multi-
factorial and has received little attention.  Radio angiography studies have 
demonstrated that both RV and left ventricular (LV) ejection fraction may be 
decreased during exercise in CF.  Hortop et al., [104] found a relation between 
expiratory flow limitation and cardiac performance during exercise in patients with 
moderate CF disease.  Endothelial dysfunction may be associated with defective 
vasodilatation of the pulmonary vessels during exercise [172].  
Impaired respiratory system mechanics, arterial hypoxemia and peripheral 
skeletal muscle dysfunction and cardiovascular factors may all contribute to exercise 
intolerance in CF.  These factors are highly interdependent and may occur in a variety 
of combinations that differ from patient to patient.  The predominant contributing 
factor may also vary among patients with different severities of CF.  Assessment of 
pulmonary and cardiovascular responses during cardiopulmonary exercise testing 
(CPET) provides an invasive sensitive tool for the detection of abnormal function and 
exercise limitation.   
The purpose of the present study was to investigate whether maximal exercise 
capacity in adults with mild, moderate and severe CF is limited by pulmonary 
mechanisms, arterial hypoxemia or cardiovascular factors.  It was hypothesised i) that 
both a ventilatory mechanical limitation and pulmonary gas exchange abnormality 
contribute to the reduced peak exercise capacity in CF patients with moderate and 
severe disease compared to healthy controls, and ii) cardiovascular abnormality also 
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contributes to the reduced peak exercise capacity in CF patients with FEV1 <30% of 
predicted. 
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Methods 
Subjects 
Adults (n=33) with different severities of CF and apparently healthy controls 
(n=34) were recruited.  CF patients were recruited from the respiratory department in 
Beaumont Hospital and were classified as having mild (FEV1 >60 % predicted), 
moderate (FEV1 40-60 % predicted) or severe (FEV1 <40 % predicted) CF.  The diagnosis 
of CF was based on clinical features, sweat test or genotyping and a pulmonary 
function test.  No other diseases that could limit exercise capacity (cardiovascular, 
orthopaedic and neuromuscular) were present.  The healthy controls were sedentary 
students recruited from a local university.  The nature and risks of the study were 
explained.  A plain language statement was read and informed consent was obtained 
in accordance with the Beaumont Hospital Ethics (Medical Research) Committee.   
Study Overview 
Subjects made a single visit to the Cardiovascular Research Unit in DCU.  
Height, weight, body composition (LBM), and pulmonary function were assessed prior 
to an incremental symptom-limited peak exercise test. 
Preparation 
Subjects abstained from alcohol and refrained from strenuous physical activity 
for 24 hours and fasted for 4 hours prior to the study visit. 
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Anthropometry 
Height and body mass were measured to the nearest 0.1 cm and 0.1 kg 
respectively using the SECA Stadiometer (Seca model 220 GmbH, Hamburg, Germany).  
Subjects were barefoot and wore light clothing.  BMI was determined as weight (kg) 
divided by height (m)2.   
Body Composition 
Double thickness subcutaneous adipose tissue was measured on the right side 
of the body using skinfold calipers (Harpenden, Cambridge Scientific Industries, MD).  
The following anatomical sites were used; chest, subscapular, mid-axillary, suprailliac, 
abdomen, triceps and thigh.  A minimum of 2 measurements were taken at each site.  
If the measurements varied by more than 2 mm, a third measurement was taken.  
Percent body fat was based on the equation proposed by Jackson and Pollack  [173]. 
Pulmonary Function Test 
Standard pulmonary function tests, including spirometry, and measurements of 
single breath DLCO (Sensormedics Vmax 229, Sensormedics Corp, CA), were 
undertaken according to previously described guidelines [174-175] and results were 
compared to normative values [176].  The spirometry manoeuvre was explained and 
demonstrated prior to the test.   
DLCO was measured using a Sensormedics Vmax 229 system.  Prior to the test, 
the gas analyzers were calibrated to room air and the breathing tube was flushed with 
0.3% CH4 and 0.3% CO.  Following a number of normal tidal breaths, subjects were 
instructed to make a full exhalation at a moderate flow rate.  This was followed by a 
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complete inhalation and holding of breath for approximately 10 seconds.  The subjects 
were then instructed to exhale completely.  The average of two trials was recorded. 
Exercise Test 
An incremental symptom-limited peak exercise test was performed on an 
electronically-braked cycle ergometer (Ergoselect 100, Ergoline GmbH) while breathing 
through a full face mask.  The protocol was designed to ensure that subjects reached 
volitional exhaustion within 8–12 minutes following 3 minutes of rest and 3 minutes 
unloading cycling.  The work rate increment ranged from 5-25 watts.min-1 depending 
on disease severity and fitness level.  Respiratory metabolic measures, HR and SpO2 
were continuously recorded throughout the test.  Peak oxygen uptake was determined 
by averaging the two highest consecutive 15 second values [177].  The normal values 
for peak V7O2 in men and women were calculated based on the equation of Hansen et 
al., [178].  The equation for men and women was W*[50.75-0.372(A)], and 
(W+43)*[22.78-0.179(A)] respectively, where W represents the weight in kilograms, 
and A represents the age in years.   
The V7O2/WR was calculated based on the equation of Hansen et al., [179]; 
∆V7O2/∆WR = (peak V7O2 - unloading V7O2)/[(T – 0.75)*S, where V7O2 is measured in ml 
per minute, T is the time of the incremental exercise, S is the slope of WR increments 
in watts.min-1, and 0.75 is the time delay before V7O2 begins to increase in a linear 
fashion.  Predicted O2 pulse was calculated based on the equation of predicted peak 
V7O2/predicted peak HR [179]. 
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The predicted maximal voluntary ventilation (MVV) was calculated as FEV1*40 
[180].  Minute ventilation was expressed relative to V7O2 and V7CO2 as ventilatory 
equivalents (V7E/V7CO2, V7E/V7O2).  The V7E/V7CO2 was calculated at the AT or at the lowest 
value attained when the AT was not achieved.  The VD volume was calculated based on 
the equation (V7E- V7A)*RR, where V7E represents minute ventilation, V7A represents 
alveolar ventilation, and RR represents respiratory rate [177]. 
Open Circuit Spirometry 
Breath by breath expired O2, carbon oxide (CO2), ventilatory volume and 
respiratory exchange ratios (RER) were determined using open circuit spirometry 
(Innocor, Innovision, Denmark).  Airflow was directed by a pneumotach using a 
differential pressure transducer (Innocor, Innovision, Denmark).  The CO2 and O2 
analysers (Oxigraph Inc, USA) were integrated within the Innocor metabolic system.  
Gases were sampled at a rate of 120 ml.min-1 and analysed by photoacoustic 
spectroscopy.  The response time of the CO2 analyser was synchronised with the O2 
analyser.  The Innocor system was calibrated prior to each test.  This involved a gas 
delay determination that assessed the specific breathing pattern of each subject and 
an O2 adjustment to the ambient air.  The system was calibrated to the manufacturer’s 
procedures using a 3 L syringe (Series 5530, Hans Rudolph Inc., Germany). 
Heart rate and SpO2% were recorded using a 12 lead ECG (Case 8000, 
Marquette GE, USA) and pulse oxymetry (Nonin 8500, Nonin Medical, INC, NH, USA) 
respectively.  Blood samples were taken from the earlobe every minute during exercise 
and used to analyse blood lactate concentration (AccuCheck Softclix Pro Lancet, Accu 
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Check, Australia).  The earlobe was sterilized with a sterile wipe and then pricked with 
a lancet (AccuCheck Softclix Pro Lancet, Accu Check, Australia) to promote blood flow.   
Determination of Anaerobic Threshold 
The V-slope method described by Beaver et al. (1986) was used for the 
determination of anaerobic threshold (AT) [181].  This method involves the analysis of 
CO2 elimination (V7CO2) relative to O2 uptake (V7O2).  By plotting V7CO2 against V7O2, the 
initial slope of 1.0 is followed by a steeper slope when lactic acid is buffered by 
bicarbonate, and CO2 is formed.  Two regression lines were plotted; one using the 
upper data points and the other using the lower data points.  The intersection of these 
two regression lines was used to identify the anaerobic threshold.  The AT was 
expressed as %VO2 peak predicted value.  Figure  3.1 illustrates the V-slope method of 
determining the AT in a single subject.  
 
Figure  3.1: Example of the V slope method to determine AT 
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Determination of the Lactate Threshold 
Lactate threshold (LT) was identified as the exercise intensity corresponding to 
the first significant rise or non-linear increase in blood lactate levels above resting 
values.  A two-phase linear regression model was used to determine the LT.  The 
logarithm (log10) of blood lactate was plotted against the logarithm (log10) of V7O2 [182].  
The lactate threshold was identified as the V7O2 value corresponding to the intersection 
of the two least squares regression lines fitted to the data points before and after the 
onset of a rapid increase in lactate concentration.  Figure  3.2 illustrates the method of 
determining the LT in a single individual.   
 
Figure  3.2: Example of log lactate (Log La) method to determine LT 
Rating of Perceived Exertion 
Overall ratings of perceived exertion were obtained every two minutes using 
the 15-point Borg category RPE scale.  Perceived leg fatigue and dyspnea scores were 
obtained every two minutes using the Borg CR-10 category RPE scale.  Prior to each 
test a standard set of instructions was read to each subject. 
 75 
Statistical Analysis 
Values are reported as mean ± SD.  Independent t-tests or Mann-Whitney U 
tests were used to compare the physiological responses at peak exercise between the 
combined CF patients and healthy controls.  A one way ANOVA or the Kruskall-Wallis 
test was used to compare the peak exercise response in patients of varying severity of 
CF (mild, moderate and severe) and the healthy control group.  Post hoc comparisons 
were made using a Tukey HSD with adjustments for multiple comparisons. P-value of 
<0.05 was accepted as statistically significant.  Data were analysed using SPSS (v17.0, 
SPSS Inc., IL).   
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Results 
Combined CF vs. Healthy Controls 
Anthropometric and Spirometry 
Anthropometric and spirometry data are shown in Table  3.1.  There was no 
difference in lean body mass  between the two groups.  CF patients had a lower FEV1 
%predicted (p <0.001), and FVC % predicted (p <0.001) than healthy controls.  A total 
of 16, 9 and 6 patients had pancreatic insufficiency in the mild, moderate and severe 
groups, respectively.  Of those, 3 patients had diabetes mellitus in the mild group, 2 in 
the moderate group and 2 in the severe group.  Only 1 patient (in the severe group) 
had osteoporosis.  No patient was being treated with oral corticosteroids. 
Table  3.1:  Subject characteristics 
 Experimental Groups 
 Healthy Controls Cystic Fibrosis 
Subjects (n) 34 (f=13) 33 (f=9) 
Age (yr) 22.2±3.2 24.5±6.2 
Weight (kg) 71.6±9.9 65.4±11.6† 
Height (cm) 174.6±9.4 172.2±8.0 
LBM (kg) 59.0±9.5 55.0±9.0 
FEV1 (L) 4.3±0.7 2.6±1.1 ‡ 
FEV1 (% predicted) 106.6±13.8 66.0±25.6 ‡ 
FVC (L) 5.1±1.0 3.9±1.3 ‡ 
FVC (% predicted) 108.2±13.2 85.9±22.3 ‡ 
FEV1/FVC 84.7±6.7 63.5±13.1 ‡ 
DLCO (ml.min
-I.mmHg -I) 34.5±5.7 30.1±7.6 
DLCO (% predicted) 96.4±9.8 91.1±18.4 
Values are mean ± SD; †p <0.05 vs. healthy controls; ‡p <0.001 vs. healthy 
controls 
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Peak Exercise Performance  
Peak exercise performance values for the CF and control group are shown in 
Table  3.2.  The CF patients had a lower peak V7O2/LBM (p<0.001), and peak lactate 
(p<0.001) than healthy controls.  Peak V7E, VT, SpO2%, and O2 pulse were lower 
(p<0.001) in CF patients than the control group.  The AT% based on predicted peak VO2 
was lower (p<0.001) in CF patients than the control group. 
Table  3.2:  Physiological responses at peak exercise in CF and healthy controls 
 Experimental Group 
 Healthy Controls Cystic Fibrosis 
V7O2 peak (ml.kg
 -1LBM min-1) 52.2±8.9 35.5±9.5‡ 
V7O2 peak %predicted 109.3±16 72.5±18.9‡ 
Workrate (watts)  251.5±55.3 143.2±62.4‡ 
Lactate (mmol/L) 10.3±1.7 7.0±2.8‡ 
AT % Predicted peak VO2 50.3±8.7 36.1±9.4‡ 
O2 Pulse (ml/b) 17.0±4.8 11.8±3.7‡ 
O2 Pulse %predicted 108±19 82±18.7‡ 
∆V7O2/∆WR (ml.min
-1.w-1) 12.2±2 10.3±2‡ 
RER 1.2±0.9 1.14±0.1 
V7E (L.min
-1) 111.0±29.1 80.1±28.1‡ 
RR (f.min-1)  44.2±8.5 44.8±7.8 
V7E/MVV (%) 64.6±16.6 82.1±18.0‡ 
VT, (L)  2.6±0.7 1.8±0.7‡ 
VT max/VC  50.0±9.8 45.7±9.3 
VD/VT 0.15±0.04 0.2±0.06‡ 
SpO2 % 97.6±1.0 93.9±4.9‡ 
V7E/V7CO2 @AT  24±2 30±4‡ 
PETCO2 (mmHg) 39.6±5.3 39.4±4.8 
Values are mean ± SD; ‡p <0.001 vs. healthy controls 
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Relation between Variables   
Peak V7E/MVV% was inversely related to FEV1%predicted (r=-0.65; P<0.001) as 
shown in Figure 3.3.  Table  3.3 summarizes the correlations between selected 
parameters and V7O2/LBM in CF patients at peak exercise.  Peak V7O2/LBM was related 
to VTmax/VC (r=0.58; p<0.01) (Figure  3.4), and inversely related to V7E/V7CO2 at AT (r=-
0.44; p<0.05) (Figure  3.5), and VD/VT (r=-0.52; p<0.01) (Figure  3.6).  There was no 
relation between peak V7O2/LBM and PETCO2. (Figure  3.7).  There was positive relation 
between O2 pulse %predicted to FEV1 % predicted (r=0.52; P<0.01) (Figure  3.8).  
 Table  3.3: Correlation between selected parameters during exercise in  
CF patients 
 
V7O2 (ml kg
-1 LBM min-1) Lactate (mmol L-1) 
V7E/V7CO2 @AT -0.44* 0.81** 
VD/VT -0.52** 0.72** 
VT max/VC    0.58** 0.73** 
PETCO2 (mmHg) -0.01 -0.71** 
* p <0.05; ** p <0.01 
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Figure  3.3: Relation between peak V7E/MVV% and FEV1%predicted in CF patients. 
The dashed line indicates the V7E/MVV at 85% 
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Figure  3.4: Relation between peak V7O2 ml kg
-1 LBM min-1 and peak VT max/VC in CF 
patients 
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Figure  3.5: Relation between peak V7O2 ml kg
-1 LBM min-1 and V7E/V7CO2 at the AT in CF 
patients 
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Figure  3.6: Relation between peak V7O2 ml kg
-1 LBM min-1 and VD/VT in CF patients 
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Figure  3.7: Relation between peak V7O2 ml kg
-1 LBM min-1 and PETCO2 in CF patients 
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Figure  3.8: Relation between peak O2 pulse %predicted and FEV1 %predicted in CF 
patients 
Comparisons between Different CF Severities and the Control Group 
Anthropometrics and Spirometry 
Anthropometric and lung function data are shown in  Table  3.4.  Body 
weight was lower (p<0.05) in individuals with severe CF disease than in healthy 
controls.  Spirometry values were higher (p<0.05) in the healthy controls than each of 
the CF groups.  Spirometry values were significantly different (p<0.05) between each of 
the CF groups with mild CF > moderate CF > severe CF.  DLCO was reduced (p<0.05) in 
severe CF compared to mild and moderate CF and healthy controls. 
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 Table  3.4:  Characteristics of healthy subjects and patients with different CF  
severities 
 Experimental Group 
 Healthy Cystic Fibrosis  
 
Controls 
Mild Moderate Severe 
Subjects (n) 33 (f=9) 18 (f=5) 9 (f=3) 6 (f=1) 
Age (yr) 22.2±3.2 24.9±6.4 24.8±6.4 24±6.2 
Weight (kg) 71.6±9.9 68.9±10.6 64±11.2 57.6±13.0† 
Height (cm) 174.6±9.4 174.0±7.8 171.7±6.1 173.4±8.7 
LBM (kg) 59.0±9.5 58.2±8.2 52.4±8.3 48.7±9.0 
FEV1(L) 4.3±0.7 3.4±0.8† 2.0±0.5†* 1.0±0.2‡ 
FEV1% 106.6±13.8 86.2±12.2† 50.6±7.8†* 28.5±4.9‡ 
FVC (L) 5.1±1 4.8±1.0† 3.4±0.8†* 2.3±0.5‡ 
FVC (% predicted) 108.2±13.2 103.0±11.1† 73.5±9.2†* 53.3±6.3‡ 
FEV1/FVC 84.7±6.7 71±9† 59.3±8.4†* 47.5±12.9‡ 
DLCO (ml.min
-I.mmHg -I) 34.5±5.7 30.5±4.4 33.3±10 21.6±6.8‡ 
DLCO (% predicted) 96.4±9.8 92.5±12.5 99.7±20.3 66±14.5‡ 
Values are mean ± SD; ‡ p <0.05 different from all the other groups; † p <0.05 vs. 
healthy;* vs. mild <0.05; f = female 
Peak Exercise Performance  
Peak exercise performance values are shown in Table  3.5.  Severe CF patients 
had a lower V7O2 peak/LBM (p<0.001) and peak WR (p<0.001) than the other groups.  
There was no difference in peak WR or V7O2peak/LBM (Figure 3.9) between the mild 
and moderate CF groups.  Peak lactate was significantly different between all groups 
(Table  3.5).   
The AT expressed as %predicted peak V7O2 was significantly lower in all CF 
groups than the healthy controls, and was below 40% in all CF groups.  O2pulse was 
significantly lower in all CF groups than the healthy controls.  The pattern of change in 
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O2 pulse during the increment test in the severe group was abnormal, reaching a 
plateau early in the exercise bout despite increasing WR.  Although the ∆V7O2/∆WR was 
significantly lower in the severe CF group than the healthy controls, it was still within 
the normal range.  The V7E/V7CO2 @AT was significantly higher in all CF groups than the 
healthy controls.  However there was no difference in PETCO2 between any of the 
groups during peak exercise.  V7E/MVV% was significantly higher in the moderate and 
severe CF groups than in the mild CF and healthy controls.  Heart rate reserve (HRR) 
was significantly higher in the severe group than all other groups.  
During peak exercise, the severe CF patients had a significantly lower VT, VT/VC 
ratio, higher RR/VT ratio, and VD/VT and a reduced peak SpO2% than the other CF 
groups and healthy controls.  Compared to the mild CF and healthy control groups, the 
moderate group had a significantly higher VD/VT and SpO2%.  However, the moderate 
CF patients achieved a normal VT/VC ratio and a similar peak VT to the mild CF group 
(Figure  3.10).   
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Table  3.5:  Physiological responses at peak exercise in different CF severities and 
healthy controls 
 Experimental Group 
 Healthy Cystic Fibrosis 
 Controls Mild Moderate Severe 
V7O2 peak (ml.kgLBM
-I.min -I)  52.2±8.9 39.1±6.7 † 37.8±8.7† 21.6±1.9‡ 
V7O2 peak (% predicted) 109.3±16 82.2±10.5 74.7±12.8 40.2±8.3 
Work rate (watts)  251.5±55.3 172.1±39.3 146.5±63† 51.6±16.3‡ 
Lactate (mmol.L -I) 10.3±1.7 8.8 ±1.7 † 6.5±1.9†* 2.7±0.9‡ 
AT-Predicted V7O2 peak (%) 50.3±8.7 37.9±9.9 † 36.3±7.0† #24.7±3.7‡ 
V7CO2 (L/min) 3.6±1 2.7±0.6 2.3±0.9 1±0.2 
O2 Pulse (ml.beat
 -I) 17±4.8 13.6±3.2† 10.8±2.8† 7.3±1.4†* 
O2 Pulse (%predicted) 108±32 90±13† 84±15† 55±13†* 
∆V7O2/∆WR (ml.min
-I.w -I) 12.2±2.2 10.4±1.8 10.9±2.8 9.1±1.5† 
RER 1.18±0.93 1.19±0.09 1.14±0.87 0.96±0.11‡ 
HRR 13.5±9.5 22.8±12.3 24.5±18.8 54.8±13.5 ‡ 
V7E (L/min) 111.0±29.1 95.2±19.2 78±22.6† 38.3±9‡ 
RR (f/min)  44.2±8.6 41.9±5.4 48.2±7.6 48.2±11.4 
SpO2 % 97.6±1.0 97±1.6 92.3±4.6†* 87±3.9‡ 
V7E/MVV (%) 64.6±16.6 70.8±11.8 96.6±9†* 94.6±20.9‡ 
VT, (L)  2.6±0.7 2.3±0.5 1.7±0.5† 0.8±0.17‡ 
VTmax/VC   50.0±9.8 48.1±8.7 48.6±7.5 35.3±6.8‡ 
VD/VT 0.15±0.04 0.16±0.02 0.22±0.03†* 0.3±0.52‡ 
V7E/V7CO2 @AT 23.9±2.1 29±3.7† 31±4† 33±4† 
PETCO2 (mmHg) 39.6±5.3 37.3±4.1 40.7±5.1 43.6±3 
Values are mean ± SD; ‡ p <0.05 different from all the other groups; †p <0.05 vs. 
healthy controls; *<0.05 vs. mild CF;  # only 3 patients achieved the AT 
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Figure  3.9: V7O2/LBM, V7E and RR at peak exercise in patients with different CF severity 
and healthy controls 
* p <0.05 different from all the other groups; † p <0.05 vs. healthy controls 
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Figure  3.10: VT, VD/VT and RER at peak exercise in patients with different CF severity 
and healthy controls 
* p <0.05 different from all the other groups; †p <0.05 vs healthy controls 
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Figure  3.11:  Individual changes in O2 pulse during the incremental exercise test in 
patients with severe CF* 
*All of the patients reached a plateau early during the exercise. 
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Discussion 
The present study examined the effect of pulmonary mechanisms, arterial 
hypoxemia and cardiovascular factors on maximal exercise capacity in adults with mild, 
moderate and severe CF compared to healthy controls.  The principle findings were; i) 
ventilatory mechanical limitation, arterial hypoxemia, and cardiovascular factors each 
contributed to the reduced peak exercise capacity in severe CF patients with FEV1 
<30% predicted, ii) ventilatory limitation was a major contributor to the reduced peak 
exercise capacity in patients with moderate CF.  In addition, deconditioning and a slight 
reduction in arterial saturation also contribute to an increased ventilatory demand and 
exercise intolerance in this group and iii) mild CF patients have a reduced peak exercise 
capacity that seems partly related to deconditioning. 
CF is a disease characterized by dysfunction of the small airways [73-74].  As 
the disease becomes more advanced, a decline in FEV1 is associated with greater 
inflammatory processes of the bronchial wall and destruction of the parenchyma.  This 
results in an increase in expiratory flow limitation (EFL) and a reduction in lung 
compliance during exercise [76].  The capacity to reduce EELV below the FRC is 
diminished in moderate to severe CF during exercise due to EFL [5].  As a consequence, 
VT is positioned close to the TLC on the steep portion of the pressure volume loop.  A 
higher pressure is required to increase VT at any given volume expansion [59, 183].  
Ringis et al., [7] found a lower V7O2 peak in CF patients with FEV1 <60% 
predicted than in healthy controls.  There was an increase in EELV during the 
incremental exercise test resulting in a reduction in VT and an elevation in the RR.  
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Normally, the maximum VT is reached at approximately 55% of VC, allowing 
optimization of the diaphragmatic and inspiratory intercostal muscle length at the 
onset of inspiration (61).  In the present study, reduced VT/VC at peak exercise was 
observed in severe CF patients suggesting a relatively rapid shallow breathing pattern 
that may increase the overload on the inspiratory muscles.  A reduced VT/VC may 
reflect the mechanical constraint on VT expansion during exercise, causing dyspnea 
and fatigue at a relatively low exercise intensity [5, 7].   
An increase in VD/VT is one of the major factors responsible for increased 
ventilatory demands during exercise in patients with lung disease [184].  VD/VT is an 
index of gas exchange efficiency.  An increase in VD/VT reflects an increased inefficiency 
of ventilation caused by V7A/Q mismatching.  VD/VT is also highly dependent on the 
breathing pattern.  Rapid shallow breathing increases VD/VT even without abnormal 
V7A/Q [184].  
Patients with moderate to severe CF have been shown to have an elevated 
VD/VT during peak exercise due to a low VT  and an increased RR [91].  An elevated 
VD/VT may result in a greater proportion of each breath moving in and out of the 
airway DS causing arterial hypoxemia.  In the present study, patients with severe CF 
had an abnormal increase in VD/VT than the mild and moderate CF groups.  The 
combination of an increase in VT/VC, and VD/VT and arterial hypoxemia at peak 
exercise may suggest that both a ventilatory mechanical limitation and abnormal gas 
exchange may contribute to exercise limitation in severe CF patients.  
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The V7E/V7CO2 at the AT can provide additional information on ventilatory 
efficiency during exercise.  The V7E/V7CO2 was elevated at the AT in all CF severities.  
However, in patients with severe CF, the elevated V7E/V7CO2 was accompanied by an 
elevated PETCO2.  The abnormally elevated V7E/V7CO2 in the presence of a high PETCO2 
decreases the likelihood of a hyperventilation-induced increase in V7E/VCO2 and may 
indicate i) poor ventilatory distribution, ii) areas of the lung with high V7A/Q, or iii) an 
increase in DS.  These factors may contribute to an increased ventilatory demand at 
any given exercise capacity and may affect exercise performance in patients with 
severe CF.   
Cardiovascular factors may also affect exercise performance in CF patients.  
Pulmonary vascular destruction with reduction in the area for gas exchange or a 
decrease in compliance leads to increased vascular resistance and hypertension in 
severe CF patients [185].  Endothelial dysfunction in the pulmonary arteries is common 
in end stage lung disease and may be related to abnormal CFTR function in the 
pulmonary arteries [186].  An impaired vasodilatory response has been found in 
pulmonary vessels during exercise, even in patients with mild to moderate CF disease 
[172].  
O2 pulse is a commonly used non-invasive method to examine the 
cardiovascular responses during exercise.  The peak O2 pulse was at the lower range of 
the normal predicted value in the mild and moderate CF groups.  There was a 
reduction in peak O2 pulse in the severe CF.  In addition, the pattern of change in O2 
pulse was abnormal in severe CF, reaching a plateau during early exercise despite an 
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increasing WR.  A low, unchanging O2 pulse with increasing WR indicates a reduction in 
maximal SV.  There is evidence that the slope of the VO2-HR relation rather than the 
maximal O2 pulse may provide a more reliable estimation of the cardiovascular 
response during exercise in healthy individuals [187] .  Several factors may affect O2 
pulse during exercise.  These include heart disease, deconditioning, ventilatory 
limitation, and possibly even the hemodynamic consequence of dynamic 
hyperinflation.  However, factors that affect the arterial-mixed venous oxygen content 
including abnormal O2 utilization, desaturation, and anaemia may also impact O2 pulse.  
An abnormal O2 pulse pattern in severe CF can be considered an indication of 
impaired pulmonary hemodynamics.  Defective compliance of the pulmonary vascular 
beds may reduce the O2 pulse, indicating a reduction in SV during exercise.  Several 
studies have demonstrated resting right ventricular dysfunction in severe CF [188-189].  
In severe COPD, right ventricular afterload during exercise is increased because of the 
increased pulmonary vascular resistance associated with breathing at lung volumes 
close to total lung capacity.  Although left ventricular dysfunction is not typically found 
in mild to moderate CF, SV during exercise has been shown to be reduced in adults 
with CF who have moderate to severe lung disease (FEV1<55% predicted) [102].   
The ∆V7O2/∆WR may provide additional information on the cardiovascular 
response during exercise.  Clinically, an abnormal slope of the ∆V7O2/∆WR relationship 
is most often due to O2 transport dysfunction.  However, less commonly, O2 utilization 
dysfunction may also be associated with an abnormal slope [190].  Indeed, muscle-
related abnormality in O2 metabolism has been found in children with mild to 
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moderate CF [10].  Although the slope of the ∆V7O2/∆WR was reduced in severe CF 
compared to the healthy controls, but was still in normal value range above 8.3 
ml.min-I.watt-I [179].  An abnormal pattern of O2 pulse combined with a reduced 
∆V7O2/∆WR may indicate abnormal cardiovascular response related to abnormal 
pulmonary hemodynamics in patients with severe CF.   
Moorcroft et al., [115] found that severe CF patients with an FEV1 >30% 
predicted were able to exercise above the LT and achieve a peak lactate value of 5.7 
mmol.L-1.  In the current study, patients in the severe CF group had an FEV1 <30% 
predicted and a peak lactate value of 2.7 mmol.L-1.  Differences in the severity of 
airway obstruction, ventilatory adaptation to exercise, and cardiovascular responses 
may help to explain the variation in peak blood lactate between the studies.  An FEV1 
<30% predicted may indicate a clinical threshold at which exercise capacity is reduced 
due to a combination of mechanical ventilatory limitation, abnormal gas exchange, and 
cardiovascular factors.  Indeed, an FEV1 <30% predicted currently serves as a primary 
criteria for lung transplantation in CF patients [56]. 
In the present study, the breathing pattern was similar in patients with mild 
and moderate CF severities.  The moderate CF patients had a V7E/MVV value 
approaching 100, suggesting ventilatory limitation to exercise.  However, despite the 
appearance of a ventilatory limitation, peak exercise capacity was similar to the mild 
CF group.  The ability of the moderate CF group to increase VT/VC ratio during exercise 
may help to explain the similar peak exercise capacity in the moderate and mild CF 
groups.  Compared to the control group, patients with moderate CF had a higher 
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V7E/V7CO2 slope accompanied by a higher VD/VT, with no change in peak ETCO2, and slight 
arterial desaturation during peak exercise.  Early onset of metabolic acidosis (lower 
AT), usually reflects deconditioning due to physical inactivity, may also contribute to 
excessive ventilatory demand [59] causing a reduced breathing reserve during peak 
exercise.  
Alterations in muscle performance may also have contributed to exercise 
intolerance in CF patients [36, 84, 106-113], and may be due in part to reduced 
physical activity levels [107].  Muscle dysfunction due to inactivity in CF may include 
muscle atrophy, muscle weakness [110], decreased number of mitochondria [8, 10, 
110-111], and an increased reliance on anaerobic glycolysis [8, 111].  In the present 
study, the mild CF group had a reduced peak V7O2, reduced AT, slightly elevated 
V7E/V7CO2 accompanied by hyperventilation.  There was no evidence of pulmonary 
limitation in the mild CF group during peak exercise.  Therefore, it seems that 
individuals with mild CF have a reduced peak exercise capacity related to 
deconditioning.  
Some studies involving CF have found evidence of an intrinsic abnormality in 
muscle function independent of deconditioning [8, 10, 109-110].  Compared to healthy 
individuals, CF athletes with good nutritional status and a preserved pulmonary 
function have lower anaerobic power and maximal leg strength, and a reduced 
mitochondrial oxidative metabolism [8].  Abnormal expression of CFTR in skeletal 
muscle may be responsible for the reduction in oxidative and anaerobic metabolism 
due in part to ATPase hydrolysis by CFTR proteins [116].  The current study was not 
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designed to investigate the mechanism responsible for the alterations in muscle 
performance and further research is required to address this issue. 
Limitations of the Study 
• MVV was not directly measured, but was estimated by multiplying FEV1 by 40.  
It is well established that MVVs estimated using this formula is similar to 
directly measured values in patients with COPD [180, 191].  
• Dynamic hyperinflation was not directly measured during the exercise test.  
The VT/VC ratio was used to indicate the ventilatory constraints on VT 
expansion during exercise.   
• The accuracy and reliability of the non-invasive estimation of SV using O2 pulse 
may be limited in patients with severe arterial hypoxemia [187, 192].  Without 
directly measuring the arteriovenous O2 content, changes in O2 pulse as an 
indicator abnormal SV response may be underestimated.   
• The VD/VT calculated from expired gas measurements, such as PETCO2, may be 
underestimated.   
Summary 
Peak exercise capacity was lower in each of the CF groups compared to healthy 
controls.  The lower exercise capacity in CF patients with an FEV1 <30% can be partly 
explained by i) an inability to increase VT, ii) abnormal gas exchange, and iii) impaired 
cardiac response (decrease in O2 pulse).  Ventilatory limitation, abnormal gas 
exchange, and deconditioning were all associated with the lower exercise capacity in 
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moderate CF.  Deconditioning was the primary exercise limitation in patients with mild 
CF.   
Exercising training is an intervention that can be used to break the vicious cycle 
of skeletal muscle deconditioning, progressive dyspnea, and improve symptoms and 
activity levels in CF patients.  Exercise training can reduce ventilatory demand by 
decreasing the respiratory rate and improving aerobic capacity.  The provision of 
supplemental oxygen may potentiate the effect of exercise in patients with CF.  
Supplemental O2 may reduce DH and improves exercise tolerance in flow-limited 
patients.  The reduction in submaximal V7E by reducing the breathing frequency may 
delay the rate of DH and the onset of critical ventilatory constraints that limit exercise.  
Supplemental O2 may also increase SV and exercise tolerance by reducing pulmonary 
vascular resistance 
The results of the present study indicate that increasing VT in patients with 
moderate to severe CF, will significantly improve exercise performance.  Interventions 
are required to increases VT during exercise while at the same time delaying 
respiratory muscle fatigue. 
  
 95 
Chapter 4  
   Study 2  
Skeletal Muscle Function, Blood Lactate and O2 Uptake Kinetics in Patients with Mild, 
and Moderate to Severe Cystic Fibrosis 
Introduction 
Exercise intolerance is well documented in patients with CF.  In addition to a 
ventilatory limitation and/or decreased gas exchange, alterations in muscle function 
due in part to reduced activity levels or immobility [107, 110, 193] may also contribute 
to reduced exercise capacity  [36, 84, 106-113].  Muscle dysfunction can result in 
muscle weakness [110], a decreased number of mitochondria [8, 10, 110-111], and 
increased reliance on anaerobic glycolysis [8, 111].   
Muscle weakness is common in CF.  The skeletal muscle weakness may be 
related to peripheral muscle atrophy indicating that muscle disuse is a major cause of 
muscle weakness [107].  Troosters et al., [109] investigated the relation between 
physical inactivity, muscle strength and exercise tolerance in adults with mild to 
moderate CF with an FEV1 of 64%.  Physical inactivity was related to exercise 
intolerance and skeletal muscle weakness.  The impairment in muscle strength and 
exercise capacity was in excess of that expected due to inactivity.  However, in CF 
patients with an FEV1 of 94%, peripheral muscle strength was found to be normal [9]. 
Intrinsic abnormality in muscle function independent of deconditioning has also 
been found in CF patients [8, 10].  Compared to healthy individuals, CF athletes with 
good nutritional status and a preserved pulmonary function have lower anaerobic 
 96 
power and maximal leg strength, and a reduced mitochondrial oxidative metabolism 
[8].  Abnormal expression of the cystic fibrosis transmembrane conductance regulator 
(CFTR) in CF skeletal muscle may also play a role in the reduction in mitochondrial 
oxidative metabolism [116]. Other factors that may contribute to peripheral muscle 
weakness and alterations in muscle structure include malnutrition, systemic 
inflammation [117], corticosteroid use [118] and hypoxia [194].   
In addition to muscle strength and peak exercise capacity, measuring O2 uptake 
kinetics during moderate and/or heavy exercise can provide additional information on 
O2 transport and O2 utilization in skeletal muscle.  The increase in pulmonary V7O2 at 
the onset of a constant load exercise can be described by the monoexponential 
function [132].  Three phases are normally considered.  Phase I (time delay (TD)) occurs 
during the first 15-20 seconds of exercise and reflects the increase in pulmonary blood 
flow without an increase in arteriovenous O2 difference [133].  Phase II reflects the 
arrival at the lungs of the mixed venous blood and lasts from approximately 15-20 
seconds after the onset of exercise to the third minute of exercise [133].  Phase III 
begins approximately 3 minutes after the onset of exercise, and reflects the start of 
the V7O2 steady state period when the work rate is below the AT.   
At exercise intensities above the AT, V7O2 steady state is delayed or not 
achieved prior to fatigue [138].  The O2 uptake kinetics at an intensity above the AT 
(heavy exercise) are determined by the magnitude of both the primary component and 
the V7O2 slow component amplitude [138].  In healthy individuals, the primary 
component lasts 2-3 minutes following the onset of exercise and is dependent on the 
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percentage of type 1 oxidative fibres within the exercising muscle.  A higher proportion 
of type 1 fibres may accelerate the primary component kinetics.  The magnitude of the 
VO2 slow component has been described as the difference between V7O2 during 3 
minutes and 6 minutes of exercise (∆VO2 6-3min) [140] as shown in Figure  2.8.   
In order to better understand the factors that may affect exercise performance 
in patients with CF, the aim of the present study was to compare body composition, 
peak exercise capacity, muscle strength, and O2 uptake kinetics in healthy adults and 
those with CF.  Individuals with CF have altered pulmonary function, gas exchange 
dynamics and cardiovascular responses that may alter O2 uptake kinetics during 
exercise.  In addition, muscle weakness, due primarily to a reduction in LBM is more 
prevalent as the disease progresses.  It is hypothesised that compared to healthy 
individuals, i) patients with moderate to severe CF will have prolonged O2 uptake 
kinetics, increased blood lactate during constant load exercise and a reduction in 
muscle strength, and ii) patients with mild CF will have similar O2 uptake kinetics, 
blood lactate levels during constant load exercise and muscle strength. 
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Methods 
Subjects 
Adults (n=28) with different severities of CF and apparently healthy controls 
(n=19) were recruited.  CF patients were recruited from the respiratory department in 
Beaumont Hospital and were classified as having mild (FEV1 >60 % predicted), and 
moderate to severe (FEV1 <60 % predicted) CF.  CF diagnosis was based on clinical 
features, sweat test or genotyping and a pulmonary function test.  No other diseases 
that could limit exercise capacity (cardiovascular, orthopaedic and neuromuscular) 
were present.  Patients using long-term oral steroid therapy were excluded.  The 
healthy controls were sedentary students recruited from Dublin City University.  The 
nature and risks of the study were explained.  A plain language statement was read 
and informed consent was obtained in accordance with the Beaumont Hospital Ethics 
(Medical Research) Committee. 
Study Overview 
Subjects made 4 separate visits to the Cardiovascular Research Unit in DCU.  
Each session was separated by at least 3 days, and the evaluation was completed 
within 2-3 weeks.  The first visit was used to assess spirometry, single breath DLCO, 
LBM and V7O2peak.  During the second and third visit, CF patients and healthy controls 
performed a constant work load test at 50% or 70% V7O2.peak, separated by 
approximately 2-3 days.  The healthy controls also performed a 10-minute constant 
load test corresponding to 50% (50 W) and 70% (100 W) of the V7O2 peak attained by 
the CF group.  The final visit was used to assess muscle strength.   
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Preparation 
Patients abstained from alcohol and refrained from strenuous physical activity 
for 24 hours and fasted for 4 hours prior to the study visit. 
Anthropometry 
Height and body mass were measured to the nearest 0.1 cm and 0.1 kg 
respectively using the SECA Stadiometer (Seca model 220 GmbH, Hamburg, Germany).  
Subjects were barefoot and wore light clothing.  BMI was determined as weight (kg) 
divided by height (m)2.  
Body Composition 
Double thickness subcutaneous adipose tissue was measured on the right side 
of the body using skinfold calipers (Harpenden, Cambridge Scientific Industries, MD).  
The following anatomical sites were used:  chest, subscapular, mid-axillary, suprailliac, 
abdomen, triceps and thigh.  A minimum of 2 measurements were taken at each site.  
If the measurements varied by more than 2 mm, a third measurement was taken.  
Percent body fat was based on the equation proposed by Jackson and Pollack  [173]. 
Pulmonary Function Test 
Standard pulmonary function tests, including spirometry, and measurements of 
DLCO (Sensormedics Vmax 229, Sensormedics Corp, CA), were undertaken according to 
previously described guidelines [174-175], and the results were compared to normal 
values [176].   
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Exercise Test 
An incremental symptom-limited peak exercise test was performed on an 
electronically-braked cycle ergometer (Ergoselect 100, Ergoline GmbH) while breathing 
through a full face mask.  The protocol was designed to ensure that subjects reached 
volitional exhaustion within 8-12 minutes following 3 minutes of rest and 3 minutes 
unloading cycling.  The work rate increment ranged from 5-25 watts.min-1 depending 
on disease severity and fitness level.  Respiratory metabolic measures, HR and SpO2% 
were continuously recorded throughout the test.  Peak V7O2 was determined by 
averaging the two highest consecutive 15 second values.  The peak value for V7O2 and 
exercise WR were related to normal values [177].  The predicted MVV was calculated 
as FEV1*40 [180].  Ventilation was expressed relative to V7O2 and V7CO2 as ventilatory 
equivalents (V7E/V7CO2, V7E/V7O2).  Dead space volume (VD) was calculated based on the 
equation (VE-VA) *RR, where V7E represents minute ventilation, V7A represents alveolar 
ventilation, and RR represents respiratory rate [177]. 
Open Circuit Spirometry 
Breath by breath expired O2, CO2, ventilatory volume and RER were determined 
using open circuit spirometry (Innocor, Innovision, Denmark).  Airflow was directed by 
pneumotach using a differential pressure transducer (Innocor, Innovision, Denmark). 
CO2 and O2 analysers (Oxigraph Inc, USA) were integrated within the Innocor metabolic 
system.  Gases were sampled at a rate of 120 ml.min-1 and analysed by photoacoustic 
spectroscopy.  The response time of the CO2 analyser was synchronised with the O2 
analyser.  The Innocor system was calibrated prior to each test.  This involved a gas 
 101 
delay determination that assessed the specific breathing pattern of each subject and 
an O2 adjustment to the ambient air.  The system was calibrated to the manufacturer’s 
procedures using a 3 L syringe (Series 5530, Hans Rudolph Inc., Germany). 
HR and SpO2 were recorded using a 12 lead ECG (Case 8000, Marquette GE, 
USA) and pulse oxymetry (Nonin 8500, Nonin Medical, INC, NH, USA) respectively.  
Blood samples were taken from the earlobe every minute during exercise, and at 
minutes 2, 5, 7, and 10 during the recovery period, and used to analyse blood lactate 
concentration (AccuCheck Softclix Pro Lancet, Accu Check, Australia).  The earlobe was 
sterilized with a sterile wipe and then pricked with a lancet (AccuCheck Softclix Pro 
Lancet, Accu Check, Australia) to promote blood flow.   
The V-slope method described by Beaver et al. (1986) was used for the 
determination of AT [181].  A two-phase linear regression model was used to 
determine the LT.  The logarithm (log10) of blood lactate was plotted against the 
logarithm (log10) of V7O2 [182]. 
Rating of Perceived Exertion 
Overall ratings of perceived exertion were obtained every 2 minutes using the 
15-point Borg category RPE scale.  Perceived leg fatigue and dyspnea scores were 
obtained every 2 minutes using the Borg CR-10 category RPE scale.  Prior to each test a 
standard set of instructions was read to each subject. 
Constant Load Exercise Tests 
CF patients and healthy controls performed 2 constant work load tests on a 
cycle ergometer for 10 minutes, separated by approximately 2-3 days.  The exercise 
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tests were performed at an intensity corresponding to 50% (light exercise) and 70% 
(moderate exercise) of the initial peak V7O2.  Healthy controls performed two additional 
constant load exercise tests at the same absolute workrate corresponding to 50% 
V7O2peak (50W) and 70% V7O2peak (100W) of the CF patients.  For the light exercise, it 
was assumed that patients exercised at an intensity that was below the AT.  
Respiratory metabolic measures, HR and SpO2% were continuously recorded 
throughout each test.  RPE, dyspnea score and leg fatigue were recorded every 5 
minutes and blood samples were taken every minute.    
Oxygen Uptake Kinetics  
A nonlinear least-square algorithm as described in the following 
monoexponential equation was used to fit the data from t = 0 sec to t = 600 sec:  
O2 (t) =  O2 baseline + A • (1-e-t/τ) 
Where O2 (t) represents the absolute O2 at a given time t; O2 baseline represents the 
mean O2 in the baseline period (the final 90 seconds of exercise preceding the 
transition to the higher work rate);  A represents the response amplitude and τ 
represents the MRT.  The end-exercise V7O2 was defined as the mean V7O2 measured 
over the final 30 seconds of the tenth minute during light exercise, and the final 30 
seconds of the sixth minute during moderate exercise.  An iterative process was used 
to minimize the sum of the squared errors between the fitted function and the 
observed values.  MRT indicates the time taken for O2 to reach 63% of the response 
amplitude from the onset of exercise with no distinction made for the various phases 
of the response [135].  The MRT derived was used to calculate the oxygen deficit (O2D) 
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using the equation: O2D = MRT*∆V7O2, where MRT represents the mean response time, 
and ∆V7O2 represents the amplitude above baseline level.  The amplitude of the slow 
component was described by the difference between V7O2 during 3 minutes and during 
6 minutes of exercise (∆V7O2 6-3min).   
Muscle Strength and Endurance 
Subjects performed a bilateral maximal isokinetic and isometric strength test, 
and a bilateral isokinetic endurance test.  Isokinetic strength was determined using 
concentric contraction of the quadriceps femoris (knee extension) and hamstring (knee 
flexion) muscle using an isokinetic dynamometer (Biodex System 3, Biodex Medical 
System, NY, USA).  Subjects performed 5 repetitions at 60°.sec-I and 180°.sec-I.  The 
rest period between trials was 90 seconds.  The highest peak torque (Nm) generated 
was recorded.   
Maximum voluntary isometric contraction peak torque (Nm) was assessed with 
the knee flexed at an angle of 60°.  Subjects warmed-up with 3 submaximal 
contractions and then performed 3 consecutive maximal contractions of 5 seconds 
duration with a 60 second rest period between repetitions.  The highest peak torque 
(Nm) generated was recorded.  Muscle endurance was determined using concentric 
contraction of the quadriceps femoris (knee extension) and hamstring (knee flexion).  
Subjects performed 20 repetitions at 240°.sec-I.  
Statistical Analysis 
Independent t-tests were used to compare the physiological responses at peak 
exercise between the combined CF patients and healthy controls.  A one way ANOVA 
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was used to compare the peak exercise response in patients of varying disease severity 
(mild, moderate to severe) and the healthy control group.  Post hoc multiply 
comparison was made using a Tukey HSD.  P<0.05 was accepted as statistically 
significant.  Values are reported as mean ± SD.  Data were analysed using SPSS (v17.0, 
SPSS Inc., IL).   
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Results 
Anthropometric and Spirometry Data  
A total of 28 CF patients and 19 healthy controls completed the study.  
Approximately one third (n=16) of the CF patients had mild disease severity and 12 had 
moderate to severe disease severity.  Since only 4 of the patients with severe disease 
severity completed all 4 study visits, the data from the moderate and severe groups 
were combined for statistical analysis.  Anthropometric and spirometry data are 
summarized in Table  4.1.  There was no difference in height, weight, LBM, % fat and 
DC between the combined CF group and healthy controls.  Each of the measured 
spirometry parameters were lower (p<0.001) in the combined CF than healthy 
controls, and in the moderate to severe CF group and healthy controls.  FEV1% 
predicted, FVC %predicted and FEV1/FVC were lower (p<0.001) in the mild CF than 
healthy controls.  Diffusion capacity, weight and LBM were significantly different 
between moderate to severe CF and healthy controls 
. 
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Table  4.1:  Subject characteristics in different CF severities and healthy controls 
 Experimental Group 
 Healthy Cystic Fibrosis 
  Combined Mild Moderate & Severe 
Subjects n 19 (f=8) 28 (f=9) 16 (f=4) 12 (f=4) 
Age (yr) 22.6±3.2 24.9±5.7† 24.8±6.4 25.9±6.1† 
Weight (kg) 71.6±9.9 66.1±11.3 70.4±11.2 60.5±9.3†* 
Height (cm) 173.6±8.8 172.2±7.8 174.3±8.5 169.5±6.1 
LBM (kg) 58.9±8.8 55.1±8.9 58.5±8.8 50.5±7.7†* 
Fat % 17.8±5.3 17.7±7.1 18.5±8.2 16.5±5.2 
FEV1(L) 4.3±0.7 2.6±1.1‡ 3.4±0.8† 1.6±0.5‡* 
FEV1% 107.4±13.8 66.4±25.1‡ 84.5±14.5‡ 42.4±12.4‡* 
FVC (L) 5.1±1.0 3.9±1.3‡ 4.7±1 2.9±0.8‡* 
FVC (% predicted) 107.4±15.6 85.5±19.7‡ 98.8±9.2‡ 66.5±12.1‡* 
FEV1/FVC 84.7±6.7 64.5±12.7‡ 71±8.4‡ 55±12.9‡* 
DLCO (ml.min
-1.mmHg-1) 31.0±3.6 29.8±7.8 31.1±6.4 28.1±9.2‡ 
DLCO (% predicted) 96.6±11.5 90.3±18.9 93.6±15.6 86.1±22.3‡ 
Values are mean ± SD; † p <0.05, ‡ p <0.001, vs. healthy controls, * p <0.05 vs. mild CF
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Peak Exercise Performance  
Peak exercise performance data are shown in Table  4.2.  Pulmonary, metabolic 
and cardiovascular responses at peak exercise were lower in the combined CF group 
than in healthy controls (p<0.001), and in the moderate to severe group than the 
healthy controls.  Peak exercise capacity, AT% predicted V7O2 peak and O2 pulse were 
significantly lower in patients with mild CF than healthy controls. However, peak 
ventilatory response was similar between mild and healthy controls.   
Peak V7O2/LBM, AT% predicted V7O2 peak were similar between mild CF to 
moderate to severe CF. However, peak O2 pulse, peak lactate and peak SpO2% were 
significantly lower in moderate to severe CF than in mild CF.  Peak VT, VD/VT were 
significantly lower and were accompanied by higher V7E/V7CO2 in moderate to severe CF 
than in mild CF. 
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Table  4.2:  Physiological response at peak exercise in different CF severities and 
healthy controls    
 Experimental Group 
 Healthy Cystic Fibrosis 
 
 Combined Mild 
Moderate 
and Severe 
Subjects n 19 (f=8) 28 (f=9) 16 (f=4) 12 (f=4) 
V7O2 peak (ml.kgLBM
-I.min -I) 53.0±12.3 36.0±9.1 ‡ 39.8±7.8‡ 30.9±8.5‡ 
V7O2 peak (% predicted) 111.9±19.8 74.4±17.4‡ 83.6±12.1‡ 62.1±16.1‡ 
Work rate (watts)  251.5±68.3 147.9±61.4‡ 180.2±49.5† 104.8±47.5‡* 
Lactate (mmol.L -I) 10.3±1.7 7.2 ±2.7‡ 8.9±1.7† 4.9±2.0‡ * 
AT Predicted V7O2 peak (%) 49.1±8.0 36.8±9.7‡ 38.5±10.6† 34.2±7.7‡ 
O2 Pulse (ml.beat
 -I) 17.0±5.6 11.9±3.7† 13.5±3.5† 9.8±2.8‡* 
O2 Pulse (%predicted) 108±32 90±13† 94.5±13.5† 74.7±16.0‡* 
∆V7O2/∆WR (ml.min
-I.w -I) 12.2±2.2 10.4±1.8† 10.1±1.5† 10.5±2.4† 
V7CO2 (L.min
 -I) 3.6±1.2 2.3±0.6† 2.8±0.9† 1.7±0.7‡ 
RER 1.16±0.1 1.15±0.1 1.19±0.1 1.1±0.1* 
HR (b.min -I) 187.7±9.3 167.1±18.1‡ 173.2±11.7† 159.0±22.3‡ 
V7E (L.min
 -I) 114.9±39.0 82.0±27.0‡ 96.0±20.7† 63.4±23.2‡ 
RR (f.min -I) 45.4±10.1 45.7±7.8 42.8±5.5 49.6±8.9 
SpO2 % 97.6±1.5 93.9±4.6‡ 96.0±4.6†* 91.0±4.7‡ * 
V7E/MVV (%) 66.6±21.7 83.7±19.0‡ 72.7±14.2 98.3±14.2‡ 
VT, (L)  2.6±0.7 1.9±0.5‡ 2.2±0.5 1.3±0.5‡* 
VT/VC % 49.6±6.2 46.3±9.4 48.4±8.3 43.5±10.3 
VD/VT 0.14±0.04 0.2±0.06‡ 0.16±0.03 0.25±0.59‡* 
VE/V7CO2@ AT 23.7±1.9 30.1±4.3‡ 28.7±3.8‡ 32.2±4.3‡* 
PETCO2 (mmHg) 38.9±5.2 39.1±4.8 37.8±5.3 41.0±3.9 
Values are mean ± SD; † p <0.05, ‡ p <0.001, vs. healthy controls, * p <0.05 vs. mild CF 
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Muscle Strength and Endurance    
The muscle strength and endurance results are shown in Table  4.3 and Table 
 4.4 respectively.  Quadriceps and hamstring maximal isokinetic strength (60°/s and 
180°/s), isometric strength and muscular endurance were significantly higher in the 
control group than both the combined CF patients and patients with moderate to 
severe CF.  With the exception of left quadriceps peak torque at 60°/s, and right 
hamstring peak torque at 60°/s and 180°/s, there was no difference in maximal 
strength or endurance between the patients with mild CF and healthy controls. 
 
Table  4.3: Quadriceps strength and endurance in different CF severities and healthy 
controls 
 Experimental Group 
 Healthy Cystic Fibrosis 
  
Combined Mild 
Moderate 
and Severe 
Subjects n 16 (f=8) 26 (f=5) 14 (f=3) 12 (f=1) 
Quadriceps right leg     
Peak torque 60°/s (Nm) 183±55 139±45† 156±45 116±35 
Peak torque 180°/s (Nm) 122±39 97±35† 109±40 90±29† 
Total work  240°/s (j) 2336±607 1962±716
† 
2174±811 1672±447† 
Isometric Peak torque 60°/s (Nm) 182±50 155±54† 167±63 136±32 † 
Quadriceps left leg     
Peak torque 60°/s (Nm) 180±52 128±40† 140±38† 110±34‡* 
Peak torque 180°/s (Nm) 126±35 92±34† 101±44 78±29† 
Total work  240°/s (j)  2138±558 1875±726 2078±773 1589±550‡ 
Isometric Peak torque 60°/s (Nm) 188±63 151±54† 163±61 132±36 † 
Values are mean ± SD; † p <0.05, ‡ p <0.001, vs. healthy controls, * p <0.05 vs. mild CF 
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Table  4.4: Hamstring strength and endurance in different CF severities and healthy 
controls 
 Experimental Group 
 Healthy Cystic Fibrosis 
  
Combined Mild 
Moderate 
and Severe 
Subjects n 16 (f=8) 26 (f=5) 14 (f=3) 12 (f=1) 
Hamstring right leg     
Peak torque 60°/s (Nm) 102±26 73±23‡ 82±23† 60±16‡ 
Peak torqu180°/s (Nm) 75±24 58±22† 67±22‡ 46±15‡* 
Total work  240°/s (j) 1440±427 981±498† 1124±561 773±304‡ 
Hamstring left leg     
Peak torque 60°/s (Nm) 95±28 67±25† 77±26 54±16‡ 
Peak torque 180°/s (Nm) 76±23 53±22† 61±22 42±16‡ 
Total work   240°/s (j) 1310±327 876±451† 1048±508 715±301‡ 
Values are mean ± SD; † p <0.05, ‡ p <0.001, vs. healthy controls, * p <0.05 vs. mild CF 
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Exercise O2 Uptake Kinetics  
Light Exercise 
CF patients and healthy controls undertook two 10-minute constant load cycle 
ergometer tests at 50% and 70% V7O2peak.  Healthy controls also performed two 
additional constant load exercise tests at the same absolute workrate corresponding to 
50% V7O2peak (50W) and 70% V7O2peak (100W) of the CF patients.  
Exercise response O2 uptake kinetics during the constant load exercise test at 
50% V7O2 peak for CF patients and at 50 W for healthy controls are shown in Table  4.5.  
MRT was similar between the combined CF and healthy controls.  The O2D per unit 
work rate was higher (p <0.05) in the moderate to severe CF than mild CF (p <0.05) and 
healthy controls (p <0.05).  SpO2% at 180 seconds was lower (p <0.001) in the 
moderate to severe CF group than healthy controls (p <0.001).  Exercise response V7O2 
uptake kinetics were similar between mild CF and healthy controls. 
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Table  4.5: V7O2 uptake kinetics during light exercise at 50% V7O2 peak in CF and same absolute workrate  
in healthy individuals 
 Experimental Group 
 Healthy Cystic Fibrosis 
  
Combined Mild 
Moderate 
and Severe 
Subjects n 17 (f=9) 28 (f=5) 16 (f=3) 12 (f=1) 
Workrate (W) 50 50±22 61±19 35±16‡* 
MRT (s) 36±14 41±11 41±9 42±14 
V7O2 baseline (ml.min
 -I) 421±126 364±78 362±85 368±71 
Relative V7O2 amplitude (ml.min
-1.w-1) 
14.3±1.7 15.1±3.7 13.2±1.6 16.3±4.1† 
O2D (L) 0.4±0.2 0.5±0.21 0.5±0.2 0.4±0.1 
Relative O2D (L.watt
 -I) 0.008±0.03 0.01±0.004 0.008±0.02 0.012±0.05†* 
SpO2 % at minute 3 97.1±0.3 95±2.5 97±2.6 94±2‡* 
Values are mean ± SD; † p <0.05, ‡ p <0.001, vs. healthy controls, * p <0.05 vs. mild CF 
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Moderate Exercise 
Exercise response O2 uptake kinetics for CF patients during the constant load 
exercise test at 70% V7O2 peak and for healthy controls at 100 W are shown in Table 
 4.6.  At the same absolute work rate (100 W), MRT was lower (p<0.001) between the 
combined CF and healthy controls.  The O2D per unit work rate was higher (p<0.001) in 
the moderate to severe CF than in mild CF and healthy controls.  Lactate levels during 
the last 15 seconds of the sixth minute were higher in the combined CF ( <0.001) than 
in healthy controls, and in moderate to severe CF than in healthy controls (p<0.05). 
The V7O2 slow component response during constant load exercise at 70% V7O2 
peak in CF patients and in healthy controls is shown in Table  4.7.  The V7O2 slow 
component amplitude per unit work rate was higher (p< 0.05) in the combined CF than 
healthy controls (p<0.05), and in moderate to severe CF than in healthy controls (p< 
0.05).  SpO2% at 360 seconds was lower (p <0.05) in the combined CF (p <0.05) than in 
healthy controls, and in moderate to severe CF than in mild CF (p <0.05). 
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Table  4.6: V7O2 uptake kinetics during moderate exercise at 70% V7O2 peak in CF and same absolute  
workrate in healthy individuals 
 Experimental Group 
 Healthy Cystic Fibrosis 
  
Combined Mild 
Moderate 
and Severe 
Subjects n 16 (f=8) 26 (f=5) 14 (f=3) 12 (f=1) 
Workrate (W)  100 100±42 123±32† 72±32‡* 
MRT (s) 39±12 60±10‡ 59±8‡ 60±11‡ 
Resting V7O2 (ml.min
 -I) 402±120 393±93 387±106 399±78 
Relative V7O2 amplitude (ml.min
-1.w-1) 13.1±1.6 13.2±1.6 12.6±1.15 13.9±2 
O2D (L) 0.8±0.2 1.2±0.5† 1.5±0.5‡ 1±0.3 † * 
Relative O2D (L.watt
 -1) 0.008±0.02 0.013±0.003‡ 0.012±0.002‡ 0.014±0.003‡ 
Lactate at 6 min (mmol.L-1) 3.1±1.5 5.9±2.1‡ 6.6±2.3 5.1±1.6† 
Values are mean ± SD; † p <0.05, ‡ p <0.001, vs. healthy controls, * p <0.05 vs. mild CF 
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Table  4.7:  Exercise response during the V7O2 slow component phase at 70% V7O2 peak in CF and healthy individuals 
 Experimental Group 
 Healthy CF 
  
Combined Mild 
Moderate 
and Severe 
Workrate (W)  193±52 100±42 123±32† 72±32‡* 
Relative ∆V7O2end-3min (L.min
-1.w-1) 0.871±1.073 1.442±0.761† 1.382±0.648 1.511±0.900† 
Lactate at 6 min (mmol.L -I) 7.2±1.7 5.9±2.1 6.6±2.3 5.1±1.6† 
SpO2 % at 6 min 97±0.5 93±4† 95±2 90±5†* 
Values are mean ± SD; † p <0.05, ‡ p <0.001, vs. healthy controls, * p <0.05 vs. mild CF 
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Relation between Variables in CF Patients 
Quadriceps and hamstring maximal isokinetic and isometric strength were 
positively correlated with LBM (Figure  4.1) and FEV1% predicted (Table  4.8).  There was 
a significant relation between quadriceps peak torque 60°/s and V7O2 peak relative to 
LBM (r=0.53; p<0.01).  The O2D per unit WR was inversely correlated (r=-0.48; p<0.05) 
to SpO2% at minute 3 of light constant load (50 W) exercise (Figure  4.2).  The MRT 
during moderate exercise was inversely correlated with the peak O2 pulse (r=-0.53; 
p<0.01). 
Table  4.8:  Correlation between exercise variable in CF patients 
 
LBM 
FEV1% 
Predicted 
Quadriceps   
Peak torque 60°/s (Nm) 0.78** 0.57** 
Isometric Peak torque 60°/s (Nm) 0.71** 0.46* 
Total work  240°/s (j) 0.84** 0.54** 
Hamstring   
Peak torque 60°/s (Nm) 0.8** 0.55** 
Total work 240°/s (j) 0.8** 0.54** 
*p <0.05; ** p <0.001 
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Figure  4.1: Relation between quadriceps peak torque 60°/s and LBM in CF patients 
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Figure  4.2: Relation between O2D/WR and SpO2 % at minute 3 of light exercise in CF 
patients 
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Figure  4.3: Relation between quadriceps peak torque 60°/s and V7O2peak in mild to 
moderate CF patients 
r=0.53; p<0.01 
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Discussion 
Exercise performance in CF is influenced by a number of factors including body 
composition, muscle function and O2 uptake kinetics.  The present study compared 
body composition, muscle strength, and peak exercise capacity in patients with mild, 
moderate and severe CF and healthy controls.  In addition, circulating levels of blood 
lactate and O2 uptake kinetics were also assessed during constant load exercise in 
adults with CF and healthy controls.  The data from the moderate and severe groups 
were combined for statistical analysis and the principles findings were that i) peak 
exercise capacity was reduced in mild, and moderate to severe CF patients compared 
to healthy controls ii) muscle strength was lower in patients with moderate to severe 
CF than healthy controls, iii) there was some evidence of reduced muscle strength in 
mild CF patients with preserved LBM compared to healthy controls iv) exercise 
response O2 uptake kinetics was slower in mild, and moderate to severe CF patients 
than healthy controls during moderate constant load exercise, and v) circulating levels 
of blood lactate were higher at the same absolute WR in mild, and moderate to severe 
CF patient than healthy controls during moderate constant load exercise.  
Peak Exercise Capacity 
It is well established that exercise tolerance is reduced in CF patients compared 
to healthy controls [115].  The reasons for the reduction in exercise tolerance are 
complex.  Compared to healthy controls, the patients with moderate to severe CF in 
the present study were ventilatory limited at peak exercise.  They had abnormal gas 
exchange, reduced O2 pulse and peripheral muscle weakness.  Interestingly, patients 
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with mild CF and normal LBM, normal O2 pulse and with no ventilatory limitation had a 
reduced AT and V7O2peak.  These findings may be related to deconditioning and/or 
skeletal muscle abnormalities.  It is possible that alterations in skeletal muscle 
metabolism may contribute to the reduced exercise capacity in the mild CF group [10].   
The significantly higher V7E/V7CO2 in the mild CF group than the healthy controls 
may have resulted from an excessively high ventilation.  Pianosi, et al., [195] found 
abnormalities in CO2 set point during exercise in CF patients.  It is possible that the 
elevated VE, assuming a normal DS (VD/VT = 0.16) may have occurred due to a change 
in the chemoreceptor set point for PaCO2.[195].  The low V7O2peak found in the mild CF 
group may indicate low levels of conditioning that may also help to explain the 
elevated V7E/V7CO2. 
Peripheral Muscle Strength 
Muscle atrophy has been shown to have a negative impact on strength in 
patients with CF [3, 34, 198].  We found that the reduction in lower limb muscle 
strength and endurance in moderate to severe CF was related to LBM.  Despite having 
a preserved LBM, the mild CF group had a reduction in left quadriceps peak torque at 
60°/s, and right hamstring peak torque at 60°/s and 180°/s compared to the healthy 
controls.  These differences may be due to alterations in biochemical or molecular 
signalling in the skeletal muscle of CF patients.  Future investigations should 
incorporate muscle biopsy sampling in order to examine the changes in the 
morphological, biochemical and metabolic properties of skeletal muscle in CF.  
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A number of previous studies have examined muscle function and strength in 
CF patients [81, 196-197].  In many instances the respiratory muscle in the CF patients 
had a trained phenotype, probably in response to the increased work of breathing 
associated with the disease [81, 196-197].  In the present study, quadriceps strength 
was significantly related to VO2peak/LBM.  Muscle strength is also related to exercise 
capacity in children with CF, even in the absence of diminished pulmonary or 
nutritional status [110].  The reduction in muscle strength in the moderate to severe 
CF group may have contributed to their exercise intolerance in the present study. 
Muscle weakness in CF may be related to inactivity [9], malnutrition, systemic 
inflammation [12], corticosteroids [13], and hypoxia [194].  There is evidence that 
physical inactivity is an important factor contributing to exercise intolerance and 
skeletal muscle weakness in adults CF [109].  An increase in systemic inflammation 
may also contribute to muscle atrophy in respiratory and non-respiratory chronic 
diseases.  Defrense et al., [117] found a relation between the severity of lung disease 
in mild to moderate CF and inflammatory cytokines, including IL-6 and TNF-α. 
However, they did not find a relation between inflammatory cytokines and lean body 
mass and muscle strength of the diaphragm, biceps and quadriceps.  After adjusting 
for FEV1% predicted and nutrition status, Barry et al., [118] found that the 
administration of 5.1 mg/day of corticosteroid over 12 a month period resulted in a 
reduction in muscle strength in CF patients.  The use of corticosteroids can be ruled 
out as a putative mechanism to explain the decrease in muscle strength in the CF 
group in the present study since none of the study participants were taking oral steroid 
medication.  The current study was not designed to investigate the mechanisms 
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responsible for muscle weakness in CF, and further research is required to address this 
issue.  
Exercise Response O2 Uptake Kinetics 
Light Exercise 
Measurement of O2 uptake kinetics during light exercise can provide additional 
information on exercise limitation in CF patients.  Adequacy of O2 delivery during the 
transient phase following the onset of exercise [137] and/or activity of the intracellular 
biochemical reaction within the muscle [199] may limit O2 uptake kinetics.  The factors 
that determine the speed of V7O2 uptake kinetics in CF at light exercise intensities are 
not well understood.  There was no difference in MRT between patients with CF and 
healthy controls during light exercise below the AT.  However, patients with moderate 
to severe CF had a larger O2D per unit WR than mild CF and healthy individuals.  This 
was accompanied by a small reduction in SpO2% at minute 3 during light exercise.  The 
inverse relation between O2D per unit WR and SpO2% at minute 3 may indicate that an 
impaired O2 delivery due to abnormal gas exchange may contribute to slower O2 
uptake kinetics in moderate to severe CF.  Another potential explanation for impaired 
O2 delivery is pulmonary vascular alteration.  The resting DC although within the 
normal range, was significantly lower in the moderate to severe CF patients than the 
controls.  It can be speculated that the DC may deteriorate to a greater extent in 
moderate to severe CF patients than healthy controls during exercise due to an 
abnormal recruitment of the pulmonary vascular bed.  This may cause a reduction in 
O2 delivery to the exercising muscles, which may in turn affect O2 uptake kinetics in 
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these patients.  The similar MRT between patients with CF and healthy controls is in 
contrast to the results reported by Hebestreit et al., [146], who found that O2 uptake 
kinetics were slower in children with mild CF with a normal SpO2% and a normal V7O2 
peak than healthy children.  The difference in age of the CF patients may contribute to 
the different findings between the two studies.   
Moderate Exercise 
Measuring O2 uptake kinetics during moderate exercise may provide additional 
information on exercise limitation in CF patients due to the additional stress on the 
cardiopulmonary and peripheral system compared to light exercise.  The MRT was 
slower and lactate levels were higher in the CF group than healthy controls at the same 
absolute WR.  Blood lactate levels were related to the amplitude of the V7O2 slow 
component.  At the same relative WR (70% V7O2peak), the V7O2 slow component 
amplitude, relative to WR, was higher in patients with CF than healthy controls.   
The MRT is an indication of the capacity to deliver O2 to exercising muscle 
fibres, and intracellular oxidative metabolism within the muscle fibres [136-137].  The 
delivery of O2 to the exercising muscle in moderate to severe CF may be impacted by a 
reduction in both V7A and gas exchange that may result in low arterial O2 content.  In 
addition, pathological alterations within the pulmonary vasculature may reduce 
pulmonary blood flow that may negatively impact on CO.  In addition to the MRT, the 
V7O2 slow component amplitude during moderate exercise was also investigated.  
Putative mechanisms responsible for the V7O2 slow component amplitude during 
moderate exercise include: i) increased cardiac and respiratory muscle work, ii) 
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increased O2 cost of lactate catabolism [138], iii) increased activity/recruitment of type 
IIX skeletal muscle fibres, iv) the pattern of motor unit recruitment [21-22] and v) 
reduced delivery of O2 to exercising muscle [143].   
In the current study, SpO2% at the end of exercise was reduced in patients with 
moderate to severe CF.  In contrast to light exercise (50% V7O2peak), there was no 
significant relation between SpO2% and prolonged O2 uptake kinetics during the bout 
of constant load moderate exercise.  Other factors related to O2 delivery may slow the 
O2 uptake kinetics during moderate exercise in patients with moderate to severe CF.  
Abnormal pulmonary hemodynamics may alter O2 delivery to exercising muscle.  
Pulmonary hypertension has been found in 41% of CF patients with FEV1<40% [188].  
In the present study, there was a negative relation between MRT during moderate 
exercise and peak O2 pulse in patients with moderate to severe CF.  This relation may 
suggest that abnormalities of O2 delivery are a potential mechanism for the reduced O2 
uptake kinetics in this group.  
In COPD patients, a higher V7E, abnormal breathing mechanics [38-39], 
hypoxemia [150], pulmonary hemodynamics [40] and peripheral vasodilatation [154] 
may slow the response of systemic and peripheral O2 delivery to a point where the O2 
uptake kinetics might become limited by O2 availability.  Gaspar et al., [42] found that 
V7O2 kinetics during heavy exercise was slower in patients with moderate to severe 
COPD than healthy individuals due to a reduction in systemic and peripheral O2 
delivery to the exercising muscle.  Providing bronchodilator therapy before heavy 
 125 
exercise reduces lung hyperinflation and accelerates V7O2 kinetics in patients with 
moderate to severe COPD [146]. 
O2 uptake kinetics in CF may also be affected by a functional deficit within the 
exercising muscle. The reduced oxidative capacity of skeletal muscle found in CF 
athletes with good nutritional status and a preserved pulmonary function [111] 
suggests inefficient O2 utilization within the skeletal muscle.  This metabolic 
inefficiency may contribute to the slower O2 uptake kinetics and increased O2D.  The 
increased O2D would be expected to elicit a transient reliance on anaerobic energy 
sources resulting in an increase in lactate production [200]. 
A reduction in peripheral O2 delivery to the exercising muscle may also 
contribute to the higher blood lactate levels found in CF patients during moderate 
constant load exercise.  No published studies have examined peripheral blood flow 
during exercise in CF.  Peripheral blood flow, in not a factor contributing to the early 
lactate acidosis in COPD [45].  However, the fact that the premature rise in blood 
lactate during exercise in COPD is related to glycolytic enzyme activity in skeletal 
muscle [45] indicates that alterations in muscle metabolism may limit exercise 
performance in this patient cohort.  A similar derangement in muscle metabolism may 
have contributed to the higher circulating levels of blood lactate during moderate 
constant load exercise, and the lower AT in the CF group than healthy controls.   
The present study was not designed to distinguish between muscle 
deconditioning and alterations in intrinsic muscle metabolism in CF.  However, a 
number of mechanisms have been identified that may help to explain the abnormality 
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in the skeletal muscle of CF patients.  The abnormal O2 uptake kinetics found in all CF 
groups may be related to an abnormality in the CFTR protein in skeletal muscle.  
Recently, Lamhonwah et al., [39] found that CFTR is expressed in the sarcoplasmic 
reticulum of human skeletal muscle.  Lack of CFTR in the skeletal muscle of mice has 
been related to an increase in inflammatory/atrophic gene expression [40].  A putative 
defect in the efficiency of mitochondrial oxidative phosphorylation may be related to 
expression of mutated CFTR.  The CFTR protein is involved in ATP hydrolysis [116].  
Abnormality in CFTR may reduce ATP hydrolysis causing inefficient oxidative and 
anaerobic metabolism that may affect O2 uptake kinetics in CF.  
Study Limitations 
The mechanisms involved in the reduced O2 uptake kinetics in CF patients were 
not investigated due to the requirement of invasive techniques.  This will require an 
invasive study to distinguish between the abnormal O2 delivery to the exercising 
muscle and an intrinsic abnormality within the muscle.   
The response data when assessing gas and ventilatory variables on a breath-by-
breath basis reflects not only the true physiological signal of interest, but also breath-
by-breath fluctuations in breathing patterns.  Tolerance of exercise stresses may be 
restricted in moderate to severe CF patients such that the stimulus must be low and 
thus the response signal is disproportionately small. 
Summary 
Peak exercise capacity and O2 uptake kinetics are reduced in patients with mild 
and moderate to severe CF compared to healthy controls.  There was evidence of 
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muscle weakness in the mild CF group even though they have a preserved LBM and 
normal pulmonary function.  These findings suggest that diminished exercise 
performance in mild CF is at least partly due to pathophysiological factors in skeletal 
muscle that cannot fully be explained by muscle deconditioning.  In patients with more 
severe clinical symptoms, the reduction in exercise capacity may be related to a 
reduced LBM, reduced gas exchange, ventilatory limitation, and an altered 
cardiovascular response.   
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Chapter 5  
  Study 3  
Supplemental Oxygen Enhances the Effect of Interval Training on Exercise Tolerance 
and O2 Uptake Kinetics in Patients with Cystic Fibrosis 
Introduction 
Abnormal pulmonary function and decreased gas exchange may contribute to 
exercise intolerance in patients with moderate and severe CF [115].  Supplemental O2 
has recently been used as a therapeutic modality to overcome the ventilatory 
limitation during maximal and submaximal exercise in CF patients.  Moderate to severe 
CF patients with arterial hypoxemia during exercise are able to increase their peak V7E 
and V7O2peak when given supplemental O2 [4].  Furthermore, providing supplemental 
O2 during a bout of exercise at 80% peak WR improves exercise duration by 26% in 
patients with moderate to severe CF [12].  The improvement in exercise performance 
following the administration of supplemental oxygen may be due to an alteration in 
ventilatory response or an improvement in O2 delivery to the exercising muscle.  
In contrast to patients with moderate to severe CF, exercise intolerance in 
patients with mild CF is due primarily to alterations in muscle function  [36, 84, 106-
113] secondary to a reduction in physical activity levels [107].  Muscle alterations due 
to inactivity in mild CF may include atrophy, [110], decreased number of mitochondria 
[5-8] and increased reliance on anaerobic glycolysis [6-7].  Recently, some studies have 
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found evidence of an intrinsic abnormality in muscle function which occurs 
independently of deconditioning in CF [5, 7-9]. 
High intensity interval training (HIIT) involves repeated bouts of high intensity 
exercise alternated with rest periods of equal or shorter duration [201].  This type of 
training allows both sedentary and active individuals to exercise at a higher intensity 
compared to continuous exercise.  Traditionally, HIIT has been used to improve 
exercise performance in athletes.  Recently, studies involving individuals with 
cardiovascular disease have found that HIIT is more effective that moderate intensity 
continuous training in improving mitochondrial function, %V7O2 at the AT, cardiac 
output, ejection fraction, resting SV, V7O2peak and time to fatigue (Guiraud et al., 
2010).  In contrast to cardiovascular disease, it is generally believed that high intensity 
exercise training is difficult in COPD patients with moderate to severe airway 
obstruction due to a ventilatory limitation [204].  Providing supplementary O2 may 
attenuate the ventilatory limitation and enhance training intensity and duration in 
these patients [17].  Allowing CF patients to train for a longer duration at a high 
intensity may enhance the training effect on peripheral muscles and improve 
endurance exercise performance manifested while breathing room air.  To our 
knowledge no studies have investigated the effects of HIIT on exercise performance in 
patients with CF.   
The present pilot study examined the effects of an 8 week HIIT training 
programme with and without O2 supplementation on V7O2 peak, O2 uptake kinetics, 
endurance performance and muscle strength in CF patients.  In addition, the study also 
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compared the effect of interval training with and without O2 supplementation on the 
number and duration of high intensity exercise bouts performed at baseline and week 
8.  All subjects breathed room air during the maximal and submaximal exercise tests 
performed at baseline and week 8.   
It was hypothesized that compared to HIIT while breathing normal room air, 
HIIT with supplemental O2 would result in i) a greater improvement in V7O2peak, 
O2uptake kinetics, endurance performance, and muscle strength and ii) a higher 
number and longer duration of high intensity exercise bouts at week 8.  
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Methods 
Subjects 
As a consequence of the practical difficulties in recruiting CF patients with 
moderate to severe disease, it was decided to also recruit patients with mild disease 
severity.  A total of 11 CF patients (5 female) were recruited to take part in the study.  
The patients were recruited from the respiratory department in Beaumont hospital.  
CF diagnosis was based on clinical features, sweat test or genotyping and a pulmonary 
function test.  No other diseases that could limit exercise capacity (cardiovascular, 
orthopaedic and neuromuscular) were present.  The nature and risks of the study were 
explained.  A plain language statement was read and informed consent was obtained 
in accordance with the Beaumont Hospital Ethics (Medical Research) Committee.   
Study Overview 
The study used a randomised, single blind design.  Patients were randomly 
assigned to a placebo (n=6) or O2 supplemental (O2Suppl) (n=5) group, and were 
blinded to the treatment.  They undertook interval training on a cycle ergometer 2 
days per week for 8 weeks.  Each session was approximately 1 hour in duration.   
Patients made 4 separate visits to the Cardiovascular Research Unit at DCU, 
before and after the training programme.  Each session was separated by at least 3 
days.  Patients performed the pre and post exercise evaluations while in stable health 
and not receiving antibiotic medication.  The first visit was used to measure body 
composition, assess spirometry, single breath DLCO, and V7O2peak.  During the second 
and third visits, patients performed a constant work load test at 50% or 70% V7O2peak.  
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The final visit was used to assess muscle strength and performance in a 6 minute walk 
test.   
Preparation 
Patients abstained from alcohol and refrained from strenuous physical activity 
for 24 hours and fasted for 4 hours prior to each visit.   
Anthropometry 
Height and body mass were measured to the nearest 0.1 cm and 0.1 kg 
respectively using the SECA Stadiometer (Seca model 220 GmbH, Hamburg, Germany).  
Subjects were barefoot and wearing light clothing.  BMI was determined as weight (kg) 
divided by height (m2).   
Body Composition 
Double thickness subcutaneous adipose tissue was measured on the right side 
of the body using skinfold calipers (Harpenden, Cambridge Scientific Industries, MD).  
The following anatomical sites were used:  chest, subscapular, mid-axillary, suprailliac, 
abdomen, triceps and thigh.  A minimum of 2 measurements were taken at each site.  
If the measurements varied by more than 2 mm, a third measurement was taken.  
Percent body fat was based on the equation proposed by Jackson and Pollack  [173]. 
Pulmonary Function Test 
Standard pulmonary function tests, including spirometry, and measurements of 
single breath DLCO (Sensormedics Vmax 229, Sensormedics Corp, CA), were 
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undertaken according to previously described guidelines [19-20] and results were 
compared to normative values [176].   
Exercise Test 
An incremental symptom-limited peak exercise test was performed on an 
electronically-braked cycle ergometer (Ergoselect 100, Ergoline GmbH) while breathing 
through a full face mask.  The protocol was designed to ensure that subjects reached 
volitional exhaustion within 8–12 minutes following 3 minutes of rest and 3 minutes 
unloading cycling.  The workrate increment ranged from 5-25 watts.min-1 depending 
on disease severity and fitness level.  Respiratory metabolic measures, HR and SpO2% 
were continuously recorded throughout the test.  Peak oxygen uptake was determined 
by averaging the two highest consecutive 15 second values.  The peak value for V7O2 
and exercise work rate were related to normal value [177].  The predicted MVV was 
calculated as FEV1*40 [180].  Minute ventilation was expressed relatively to V7O2 and 
V7CO2 as ventilatory equivalents (V7E/V7CO2, V7E/V7O2).  Dead space volume was calculated 
based on the equation (VE-VA)*RR, where V7E represents minute ventilation, V7A 
represents alveolar ventilation, and RR represents respiratory rate [177]. 
Open Circuit Spirometry 
Breath by breath expired O2, CO2, ventilatory volume and RER were determined 
using open circuit spirometry (Innocor, Innovision, Denmark).  Airflow was directed by 
pneumotach using a differential pressure transducer (Innocor, Innovision, Denmark).  
The CO2 and O2 analysers (Oxigraph Inc, USA) were integrated within the Innocor 
metabolic system.  Gases were sampled at a rate of 120 ml.min-1 and analysed by 
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photoacoustic spectroscopy.  The response time of the CO2 analyser was synchronised 
with the O2 analyser.  The Innocor system was calibrated prior to each test.  This 
involved a gas delay determination that assessed the specific breathing pattern of each 
subject and an O2 adjustment to the ambient air.  The system was calibrated to the 
manufacturer’s procedures using a 3 L syringe (Series 5530, Hans Rudolph Inc., 
Germany). 
HR and SpO2% were recorded using a 12 lead ECG (Case 8000, Marquette GE, 
USA) and pulse oxymetry (Nonin 8500, Nonin Medical, INC, NH, USA) respectively.  
Blood samples were taken from the earlobe every minute during exercise and used to 
analyse blood lactate concentration (AccuCheck Softclix Pro Lancet, Accu Check, 
Australia).  The earlobe was sterilized with a sterile wipe and then pricked with a lancet 
(AccuCheck Softclix Pro Lancet, Accu Check, Australia) to promote blood flow.   
Rating of Perceived Exertion 
Overall ratings of perceived exertion were obtained every 2 minutes using the 
15-point Borg category RPE scale.  Perceived leg fatigue and dyspnea scores were 
obtained every 2 minutes using the Borg CR-10 category RPE scale.  Prior to each test a 
standard set of instructions was read to each subject 
Constant Load Exercise Tests 
Participants performed 2 constant work load tests on a cycle ergometer, for 
approximately 30 minutes, separated by approximately 2-3 days.  The exercise tests 
were performed at an intensity corresponding to 50% (light exercise) and 70% 
(moderate exercise) of the initial peak V7O2.  Respiratory metabolic measures, HR and 
 135 
SpO2% were continuously recorded and values were averaged during the final 30 
seconds of the exercise bout.  RPE, dyspnea score and leg fatigue were recorded every 
5 minutes and blood samples were taken every minute.   
Oxygen Uptake Kinetics  
A nonlinear least-square algorithm, as described in the following 
monoexponential equation, was used to fit the data from t = 0 sec to t = 600 sec: 
O2 (t) =  O2 baseline + A • (1-e-t/τ) 
where O2 (t) represents the absolute O2 at a given time t; O2 baseline represents the 
mean O2 in the baseline period (the final 90 sec of exercise preceding the transition to 
the higher work rate);  A represents the response amplitude and τ represents the 
mean response time (MRT).  The end-exercise V7O2 was defined as the mean VO2 
measured over the final 30 seconds of the tenth minute during moderate exercise.  An 
iterative process was used to minimize the sum of the squared errors between the 
fitted function and the observed values.  MRT indicates the time taken for O2 to reach 
63% of the response amplitude from the onset of exercise with no distinction made for 
the various phases of the response [135].  The MRT derived was used to calculate the 
O2 deficit (O2D) using the equation: O2D = MRT*∆ V7O2, where MRT represents the 
mean response time, and ∆ V7O2 represents the V7O2 amplitude above baseline level. 
Muscle Strength and Endurance 
Patients performed a bilateral maximal isokinetic and isometric strength test, 
and a bilateral isokinetic endurance test.  Isokinetic strength was determined using 
concentric contraction of the quadriceps femoris (knee extension) and hamstring (knee 
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flexion) using an isokinetic dynamometer (Biodex System 3, Biodex Medical System, 
NY, USA).  Subjects performed 5 repetitions at 60°.sec-I and 180°.sec-I.  The rest period 
between trials was 90 seconds.  The highest peak torque (Nm) was recorded.   
Maximum voluntary isometric contraction peak torque (Nm) was assessed with 
the knee flexed at an angle of 60°.  Patients warmed-up with 3 submaximal 
contractions and then performed 3 consecutive maximal contractions of 5 seconds 
with a 60-second rest between repetitions.  The highest peak torque (Nm) was 
recorded.  Muscle endurance was determined using concentric contraction of the 
quadriceps femoris (knee extension) and hamstring (knee flexion).  Subjects performed 
20 repetitions at 240°.sec-I.  
6 Minute Walk Test 
The 6-minute walk test was performed indoors, along a flat, enclosed 30 metre 
corridor with a hard surface, according to ATS guidelines [205].  The patients were 
instructed to walk as far as possible, turning 180° every 30 metres in the allotted time 
of 6 minutes.  The total distance walked was measured to the nearest metre, and 
recorded.  Sitting HR, lactate level, and SpO2% were measured before and immediately 
after the test while in a resting position.  
Interval Training Programme 
Following a 5-minute warm-up at 5-10 W, the patients undertook 
approximately 45 minutes of interval training, followed by a 5-minute recovery period.  
Each interval training session involved a period of high-intensity cycling (HIC) at 70% 
peak WR followed by 60 seconds of low-intensity cycling (LIC) at 35% peak WR.  During 
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each training session the patients wore a nasal cannula through which medical oxygen 
(100%) or compressed air were delivered continuously at 3 L.min-1. 
The first week was used to familiarize patients with the training protocol.  HR 
and SpO2% were measured at rest and throughout each training programme.  Whole 
blood lactate levels were measured at rest and during the 15 seconds of the final HIC 
interval phase of each training session.  In addition, RPE, dyspnea, and leg fatigue were 
also measured during the 15 seconds of the final HIC interval phase of each training 
session.   
Statistical Analysis 
Baseline anthropometric, pulmonary function, V7O2peak, peak workrate, total 
endurance time, and muscle strength data were compared between the two 
experimental groups using a Mann-Whitney U test.  Within group, pulmonary and 
metabolic responses at peak exercise and at the end of the light and moderate load 
exercise sessions were compared using Wilcoxan sign rank test.  Pulmonary and 
metabolic responses during the post training constant load moderate (70% V7O2peak) 
exercise test were compared to the time the subject stopped exercising during the 
baseline test (isotime).  Significance was accepted at the level of p<0.05.  Values are 
presented as mean ± SD.  Data were analysed using SPSS (v17.0, SPSS Inc., IL).   
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Results  
Patient Characteristics and Intervention Compliance  
Nine of the original 11 participants completed the study.  One patient was 
excluded due to low compliance with the training programme and the other was 
excluded due to an atrioventricular re-entrant tachycardia.  Training sessions had to be 
rescheduled for 3 patients (2 from the O2-Suppl group) due to illness.  The compliance 
rate was 100% for the 9 patients who completed the study.   
Pulmonary function and LBM for each individual patient are shown in Table  5.1.  
Age and height were similar in both groups; 28±6 years and 168±5 cm for the O2Suppl 
group, and 27±4 year and 170±8 cm for the placebo group, respectively.   
Table  5.1:  Pulmonary function and LBM for each individual patient before training 
 LBM (kg) FEV1%  
pred 
FVC % 
pred 
DLCO % 
pred 
V9E/MVV  
(%) 
O2Suppl Group      
1 45 31 65 62 94 
2 50 86 98 84 72 
3 53 44 71 79 117 
4 54 84 102 93 59 
5 45 45 80 74 88 
Mean±SD 49.6±4.4 58.0±25.2 83.6±16.2 78.4±11.5 85.9±22.8 
Placebo Group      
1 39 31 45 47 105 
2 50 40 70 95 85 
3 41 46 56 91 81 
4 72 109 114 100 53 
Mean±SD 50.9±14.9 56.5±35.5 71.2±30.2 83.2±24.4 81.4±21.3 
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Workrate and HIC Duration  
The LIC WR and HIC WR remained constant in the O2Suppl group (40±22 W and 80±43 
W) and the placebo-group (42±20 W, 84±58 W) throughout the training period.  The 
total duration of HIC increased (p<0.05) by 150% in the O2Suppl group between week 1 
and week 8 (11±2.6 vs.29±2) (Figure  5.1).  There was no change in the total duration of 
HIC between week 1 and week 8 in the placebo group (15±4vs. ±24±9).  Blood lactate 
levels (Figure  5.2) and % peak HR (Figure  5.3) were similar during the final HIC 
repetition of the first and last training session.  
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Figure  5.1: Total duration of HIC in the O2Suppl group and the placebo group 
between week 1 and week 8 of the training programme  
(*p <0.05 vs baseline) 
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Figure  5.2: Blood lactate level during the final HIC repetition of the last training 
session in the O2Suppl group and the placebo group between week 1 
and week 8 of the training programme  
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Figure  5.3: Percent of peak heart rate during the final HIC repetition of the last 
training session in the O2Suppl group and the placebo group between 
week 1 and week 8 of the training programme  
Exercise Training and Pulmonary Function 
There was no difference in weight, LBM or pulmonary function between the 
two experimental groups at baseline (Table  5.2).  Compared to baseline values, FEV1 % 
predicted and FVC% predicted were reduced by 8% and 6% respectively (p <0.05) in 
 141 
the O2Suppl group, and did not change in the placebo group following the training 
programme (Table  5.2).  Exercise training had no effect on any of the other 
anthropometric or pulmonary function measurements. 
Table  5.2:  Weight, height and pulmonary function at rest before and after training 
 Experimental Group 
 O2 Suppl group Placebo group 
 Pre training Post training Pre training Post training 
Weight (kg) 58.6±6.8 57.8±7.6 64.2±17.5 64.9±18.0 
Lean body mass (kg) 49.6±4.4 48.9±5.1 50.9±14.9 50.7±15.0 
FEV1(L) 2.2±1.1 2.1±1.2 ‡ 2.2±1.7 2.2±1.4 
FEV1% 58.0±25.2 53.6±25.8 ‡ 56.5±35.5 55.0±27.7 
FVC (L) 3.7±1.0 3.5±1.1 ‡ 3.2±2.0 3.2±1.8 
FVC (% predicted) 83.6±16.2 78.0±16.9 ‡ 71.2±30.2 72.0±26.5 
FEV1/FVC 57.2±15.1 55.8±17.0 66.2±13.4 64.0±10.3 
DLCO ml.min
-1.mmHg-1 24.9±5.8 25.8±4.8 26.8±10.6 29.0±11.6 
DLCO (% predicted) 78.4±11.5 80.0±11.1 83.2±24.4 90.5±28.2 
Values are mean ± SD; ‡ p <0.05 vs. ore training 
Metabolic, Pulmonary and Perceptual Responses at Peak Exercise 
Metabolic, pulmonary and perceptual responses during peak exercise were 
similar in both experimental groups at baseline and did not change in response to 
training (Table  5.3). 
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Table  5.3:  Metabolic, pulmonary and perceptual responses at peak exercise before 
and after training 
 Experimental Group 
 O2 Suppl group Placebo group 
 Pre training Post training Pre training Post training 
V7O2 peak  
(ml.kg-1LBM.min-1) 31.9±11.1 33.4±11.2 32.1±5.0 33.8±10.5 
Workrate (watts) 116.6±59.4 130.6±70.4 120.7±71.2 137±100.7 
Lactate (mmol.L-1) 6.2±1.8 6.2±2.4 6.4±3.1 6±2.1 
RER 1.1±0.1 1.1±0.1 1.1±0.1 1.1±0.1 
V7E (L.min
-1) 71.3±26.7 71.9±36.3 62.5±29.3 60.6±27.6 
V7E/MVV (%) 85.9±22.8 90.1±21.1 81.4±21.3 77.7±17.4 
VT, (L) 1.5±0.8 1.5±0.9 1.6±0.8 1.7±1.3 
RR (f.min-1) 48.6±9.0 49.3±8.6 44.3±12.1 43.0±13.2 
PETCO2 (mmHg) 35.4±3.1 36.4±4.9 39.8±4.4 41.3±5.4 
V7E/V7CO2 @AT 35.7±3.9 35.1±3.8 30±4.8 30±4.3 
SpO2% 93.4±4.3 89.6±7.1 92.5±6.4 91.0±4.7 
RPE overall score 15.4±2.5 15.6±3.0 16.0±1.4 16.5±1.0 
Dyspnea score 6.6±2.1 6.2±2.3 6.0±1.2 6.2±0.9 
Leg fatigue score 7.4±1.9 7.0±2.5 6.0±1.8 6.7±1.7 
Values are mean ± SD; ‡ p <0.05 within groups pre and post training 
Constant Load Exercise Response 
Physiological and perceptual responses during light intensity constant load 
exercise are presented in Table  5.4.  Whole blood lactate, V7E, and RR were lower 
(p<0.05) at week 8 than baseline in the O2Suppl group.  MRT and O2D decreased by 
22% (p <0.05) and 26% (p <0.05) respectively in the O2Suppl group following exercise 
training.  Compared to baseline, there was no change in any of the physiological and 
perceptual responses at week 8 in the placebo group. 
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Table  5.4: Physiological and perceptual responses during light intensity constant load 
exercise 
 Experimental Group 
 O2 Suppl group Placebo group 
 Pre training Post training Pre training Post training 
Workrate (W) 37.0±21.0  41.0±23.0  
Time (min) 10.0  10.0  
V7E (L.min
-1) 32.4±2.3 28.1±4.6‡ 29.2±2.6 30.2±3.6 
VT, (L) 1.0±0.4 1.0±0.4 1.2±0.5 1.1±0.5 
RR(f.min-1) 34.8±11.3 29.6±4.6‡ 30.7±12.5 31.2±12.2 
PETCO2 (mmHg) 37.0±2.3 38.8±1.3 38.2±6.6 38.5±6.9 
SpO2% 94.0±1.5 94.4±2.4 94.5±2.6 93.5±2.6 
Lactate (mmol.L-1L) 2.6±0.8 1.5±0.3‡ 1.5±0.2 1.6±2.1 
RPE overall score 11.0±1.4 9.8±1.3 10.0±2.9 10.7±2.6 
MRT (s) 44.4±9.0 34.0±11.4‡ 45.0±16.5 39.2±14.3 
O2D (L) 0.4±0.1 0.3±0.1‡ 0.4±0.1 0.33±0.4 
Values are mean ± SD; ‡ p <0.05 within groups pre and post training 
Effect of Training on Moderate Constant Load Exercise Response 
Physiological and perceptual responses during the final 30 seconds of moderate 
intensity constant load exercise are presented in Table  5.5.  Endurance capacity, 
measured as an increase in exercise time in the constant WR test improved (p<0.05) in 
the O2Suppl group (Figure  5.4), and did not change in the placebo group (Figure  5.5).  
The improvement in endurance performance was 65% greater in the O2Suppl group 
than in the placebo group.  Compared to baseline, V7E decreased by 9% at week 8 and 
there was no change in any of the physiological and perceptual responses during the 
final 30 seconds of moderate intensity constant load exercise in the placebo group. 
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Table  5.5:  Physiological and perceptual responses during the final 30 seconds of 
moderate intensity constant load exercise  
 Experimental Group 
 O2 Suppl group Placebo group 
 Pre training Post training Pre training Post training 
Workrate (W) 79±41  88±55  
Time (min) 11.2±2.2 24.5±6.3‡ 11.5±5.8 17.8±0.5 
HR (b.min-1) 155.2±14.2 160.0±11.3 149.0±11.8 149.7±17.7 
V7E (L.min
-1) 57.6±16.9 52.6±13.4‡ 46.0±8.4 46.5±11.8 
VT, (L) 1.4±0.7 1.4±0.62 1.6±0.9 1.4±0.77 
RR(f/.min-1) 41.6±8.0 41.6±7.9 35.5±14.3 40.0±17.7 
PETCO2 (mmHg) 37.0±3.6 37.2±3.8 42.5±10.3 42.0±8.1 
SpO2% 90.2±5.6 89.4±4.4 90.2±8.9 89.5±8.3 
Lactate (mmol.L-1) 6.3±1.4 5.3±1.3 4.7±0.7 3.8±0.4 
RPE overall score 14.4±1.9 14.3±6.2 13.7±1.5 15.2±2.3 
Dyspnea score 5.4±1.9 5.2±2.2 4.0±1.1 5.7±2.0 
Leg fatigue score 5.2±1.8 4.6±1.5 4.4±1.0 4.7±1.0 
Values are mean ± SD; ‡ p <0.05 within groups pre and post training 
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Figure  5.4:  Total exercise time for identical moderate work rate before (pre 
training) and after (post training) the training programme for each 
individual in the O2 Suppl group.  The bold line represents the mean 
group value. 
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Figure  5.5:  Total exercise time for identical moderate work rate before (pre 
training) and after (post training) the training programme for each 
individual in the placebo group.  The bold line represents the mean 
group values. 
 
Effect of Training on the Isotime Physiological and Perceptual Responses during 
Moderate Intensity Exercise 
Pulmonary, metabolic and perceptual responses during the post training 
constant moderate intensity (70% V7O2peak) exercise test were compared to the time 
the subject stopped exercising during the baseline test (isotime) (Table 5.6.  ).  In the 
O2Suppl group, V7E decreased by 15% (p <0.05) (Figure  5.6), RR decreased by 12% (p 
<0.05) (Figure  5.8), and blood lactate decreased by 28% (p <0.05) (Figure  5.10) at the 
same time point that the subject stopped exercising during the baseline test.  The 
decrease in V7E was accompanied by a 21% decrease in RPE overall score (p <0.05).  
There was no change in V7E (Figure 5.7), RR, (Figure 5.9) and lactate level (Figure 5.11) in 
the placebo group in response to training.  
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Table 5.6.  Response to moderate intensity constant work rate exercise at identical 
workrate and exercise duration (isotime) 
 Experimental Group 
 O2 Suppl group Placebo group 
 Pre training Post training Pre training Post training 
Subjects (n) 5  4  
Workrate (W) 79±41  88±55  
Time (min) 11.2±2.2  11.5±5.8  
HR (b.min-1) 155.2±14.2 152.2±11.7 149.0±11.8 144.0±11.1 
O2 pulse (ml.beat
-1) 10.0±1.5 9.6±1.4 9.9±1.4 10.0±1.4 
V7E (L.min
-1) 57.6±16.9 48.0±11.7‡ 46.0±8.4 44.5±10.1 
VT, (L) 1.4±0.7 1.4±0.62 1.6±0.9 1.4±0.9 
RR(f.min-1) 41.6±8.0 35.8±6.7‡ 35.5±14.3 36.7±16.2 
PETCO2 (mmHg) 37.0±3.6 37.2±6.2 42.5±10.3 40.7±7.1 
V7E/V7CO2 33‡2.9 30±2.9‡ 30±6 30±4 
SpO2% 90.2±5.6 90.6±3.7 90.2±8.9 89.0±6.7 
Lactate (mmol.L-1) 6.3±1.4 4.4±0.8‡ 4.7±0.7 4.4±0.5 
RPE overall score 14.4±1.9 11.8±1.7‡ 13.7±1.5 14.7±2.8 
Dyspnea score 5.4±1.9 4.0±1.0 4.0±1.1 4.5±1.7 
Leg fatigue score 5.2±1.8 4.1 ±1.1 4.4±1.0 6.2±1.3 
Values are mean ± SD; ‡ p <0.05 vs pre training 
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Figure  5.6: Minute ventilation at identical moderate work rate and exercise duration 
(isotime) before (pre training) and after (post training) the training 
programme for each individual in the O2Suppl group.   
 The bold line represents the mean group value. 
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Figure  5.7: Minute ventilation at identical moderate work rate and exercise duration 
(isotime) before (pre training) and after (post training) the training 
programme for each individual in the placebo group.   
The bold line represents the mean group value. 
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Figure  5.8: Respiratory rate at identical moderate work rate and exercise duration 
(isotime) before (pre training) and after (post training) the training 
programme for each individual in O2Suppl group.   
The bold line represents the mean group value. 
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Figure  5.9:  Respiratory rate at identical moderate work rate and exercise duration 
(isotime) before (pre training) and after (post training) the training 
programme for each individual in the placebo group.   
The bold line represents the mean group value.  
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Figure  5.10: Lactate level at identical moderate work rate and exercise duration 
(isotime) before (pre training) and after (post training) the training 
programme for each individual in the O2Suppl group.  
The bold line represents the mean group values.  
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Figure  5.11: Lactate level at identical moderate work rate and exercise duration 
(isotime) before (pre training) and after (post training) the training 
programme for each individual in the placebo group.  
The bold line represents the mean group values.  
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Muscle Strength 
There was no difference in muscle strength or muscle endurance between the 
two experimental groups at baseline.  There was no change in muscle strength or 
muscle endurance in either group in response to the interval training programme 
(Table  5.6).  
6 Minute Walk Test 
There was no difference in the total distance covered between the two 
experimental groups at baseline.  Compared to baseline, there was an 8% increase 
(p<0.08) in total distance covered in the O2Suppl group and a 2% decrease in the 
placebo group (Table  5.6).  
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Table  5.6: Effect of exercise training on muscle strength 
 Experimental Group 
 O2 Suppl group Placebo group 
 Pre training Post training Pre training Post training 
Subjects (n) 5  4  
Peak torque  60°/s extension (N-m) 107±46 119±36 135±65 128±55 
Peak torque 60°  isometric (N-m) 113±37 128±25 141±117 147±72 
Total endurance Work (J) 1569±619 2005±545 2056±1468 1958±1423 
6 minute walking test (m) 580±84 623±58 632±91 619±104 
Values are mean ± SD 
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Discussion  
To our knowledge, this pilot study is the first to examine the effects of exercise 
training with supplemental O2 on maximal and submaximal exercise performance in CF 
patients.  Patients who were provided with supplemental O2 were able to maintain the 
interval training intensity for longer periods compared to patients in the placebo 
group.  The duration of high intensity interval cycling increased by 150% in the O2Suppl 
group during the 8-week training programme compared to 53% in the placebo group.  
Improvements in endurance capacity and ventilatory response to exercise were only 
evident in the group that received supplemental O2.  
Previous studies have examined the effect of supplemental O2 on acute 
exercise performance in patients with CF and chronic obstructive pulmonary disease 
(COPD).  McKone et al., [12] found that exercise duration increased by 26% during a 
single bout of exercise at 80% peak work rate in patients with moderate to severe CF.  
They speculated that the improvement in exercise performance may be due to an 
alteration in ventilatory response or an improvement in O2 delivery to the exercising 
muscle.  Supplemental O2 also increases exercise duration during a single bout of 
exercise at 50% and 75% peak work rate in COPD patients [26-27].  The improvement 
in acute exercise capacity may to be related to a delay in the initiation of ventilatory 
limitation as a result of reduced ventilatory demand.   
A number of potential mechanisms may help to explain how supplemental O2 
may reduce the ventilatory response during acute exercise in patients with COPD.  
Firstly, supplemental O2 may diminish hypoxic drive from peripheral chemoreceptors 
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due to an increase in PaO2 resulting in a decrease in respiratory rate [151].  Secondly, 
the reduced metabolic acidosis as a result of improved arterial O2 content to the active 
muscles may decrease carotid body stimulation [170].  Increasing the time available for 
expiration (TE) may also reduce RR which may delay the extent of dynamic 
hyperinflation (DH) [26-29].  Thirdly, pulmonary vasodilatation induced by O2 may 
increase CO and muscle O2 delivery, reduce lactic acid production, and decrease 
carotid body stimulation [206]. 
Studies that have examined the effect of exercise training with supplemental 
O2 in patients with COPD have been equivocal [17, 30-31].  Rooyackers et al., [207] and 
Garrod et al., [208] failed to find an additional benefit of supplemental O2 on WR 
during training, or peak exercise performance in patients with advanced COPD and 
exercise hypoxemia.  The design of these studies may have contributed to the negative 
result.  In the Rooyackers et al., study, the O2 training group did not achieve a higher 
training intensity than the control group.  The interval nature of the programme 
(maximum 3 minute exercise interval followed by a 2 minute rest interval) may have 
allowed the subjects in the control group to maintain SpO2% above 90% while 
exercising at a relatively high work rate.  The fact that workrate was not allowed to 
exceed the level at which SpO2% fell below 90% may have blunted the potential 
training benefit.   
Improvements in exercise capacity in response to exercise training have been 
shown to be related to the intensity and duration of training [209].  Subjects in the 
study by Garrod et al., [208] undertook 45 minutes of exercise training per week for 6 
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weeks at 80% of the VO2 peak achieved during a shuttle walk test.  No information was 
provided on the specifics of the training programme, or whether or not the subjects 
achieved the prescribed training intensity.   
Emtner el al., [17], used a double blind randomized control study design to 
compare the effects of 7 weeks of exercise training with and without supplemental O2 
in patients with severe COPD who did not experience hypoxemia during exercise.  
Subjects exercised 3 times per week for 45 minutes on a cycle ergometer.  Training 
with supplemental O2 allowed the patients to train at a higher intensity and improve 
submaximal exercise performance compared to training under normal atmospheric 
conditions.  The RR was lower and the VT higher during constant load submaximal 
exercise under normal atmospheric conditions following the 8-week training 
programme with supplemental O2.   
In the present study, the circulating levels of blood lactate were the same in 
both groups during the final HIC repetition at the end of the first training session and 
the final HIC repetition at the end of the last training session.  The fact that blood 
lactate values remained at a similar level despite a significant increase in HIC interval 
time over the course of the training programme provides evidence of a physiological 
training effect in the O2Suppl group.  Compared to pre-training values at the isotime 
point, VE, RR, and blood lactate levels were lower in the O2Suppl group during the post 
training light constant load exercise test and the moderate constant load exercise test.  
In participants who were ventilatory limited during exercise, a reduction in 
ventilatory demand at a moderate intensity WR may help to explain the improvement 
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in exercise tolerance following the 8 weeks of exercise training with supplemental O2.  
A reduction in the ventilatory demand would allow these patients to exercise for a 
longer duration before reaching the point of ventilatory limitation.  The reduction in 
ventilatory demand may be due in part to a delay in lactate accumulation.  Although 
arterial blood gases were not measures, it is possible that the decrease in lactate 
accumulation at the same absolute WR may have resulted in a decrease in arterial 
hydrogen (H+) concentration.  Lower levels of circulating hydrogen ions should 
decrease carotid body stimulation and subsequently decrease V7E [209].   
The reduction in RR may have also contributed to the decrease in ventilatory 
demand, leading to improved exercise performance in CF patients following exercise 
training with supplemental O2.  Since 3 of the patients in the O2Suppl group had mild to 
moderate hypoxemia during exercise, the reduced RR may have been related to an 
inhibition of carotid body stimulation resulting from the availability of supplemental O2 
during training.  Slowing the RR may lead to reduced dynamic hyperinflation (DH).  
Since the extent of DH during exercise in flow-limited patients depends on ventilation 
and the breathing pattern for a given ventilation, a reduction in ventilatory demand by 
reducing RR should delay the onset of DH.  O’Donnell et al., [210] found that a small 
reduction in ventilation decreased dynamic lung volumes that translated to 
improvements in symptoms and exercise performance, even in mildly hypoxemic 
COPD patients [59].  Alison at el., [34] showed that DH occurs in CF patients with FEV1 
<60% predicted.  It is possible that the decrease in RR during low and moderate 
constant load exercise may be associated with a reduction in DH, thus contributing to 
the overall training benefit in the hypoxemic patients in the O2Suppl group. 
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Increasing O2 delivery to exercising muscles is another putative mechanism that 
may help to explain the beneficial effect of O2 therapy during exercise training.  
Improved muscle O2 delivery during exercise may attenuate lactic acidosis and, 
thereby, reduce ventilatory stimulation.  As peak O2 pulse and peak V7O2 did not change 
following exercise training in either group, it is unlikely that cardiovascular adaptations 
could explain the improvement in exercise endurance in the O2Suppl group following 
exercise training.  Furthermore, the reduction in V7E/V7CO2 and blood lactate levels 
accompanied by no change in PETCO2 or SPO2% at isotime exercise, may indicate a 
greater peripheral (muscle) than central contribution (pulmonary and cardiovascular) 
to the improvement in exercise performance.  
Slow O2 uptake kinetics have previously been found during acute exercise in 
patients with CF [146].  The present study is the first to provide information on O2 
uptake kinetics in CF patients following a training programme.  MRT was used to 
determine the O2 uptake kinetics.  MRT is a combination of phase I and subsequent 
exponential phase II, and is dependent on O2 delivery to the exercising muscle and 
muscle O2 metabolism.  
The acceleration in O2 uptake kinetics found in the O2Suppl group following the 
training programme indicates an improvement in skeletal muscle and/or 
cardiovascular function.  Intramuscular changes associated with high intensity training 
may lead to more efficient oxidative metabolism and faster intramuscular O2 uptake 
kinetics following exercise training in healthy individuals [211].  Furthermore, a 
reduction in lactate level at light and moderate constant load exercise may be 
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associated with faster O2 uptake kinetics, indicating an improvement in aerobic 
metabolism following the training programme.  It is possible that the failure to alter O2 
uptake kinetics in the placebo group was due to the fact that they were unable to 
sustain an exercise intensity required to achieve a sufficient overload to stimulate 
adaptive changes in the skeletal muscle.  It is possible that exercise training with 
supplemental O2 may be related to a decrease in ventilatory demand secondary to 
adaptive changes in skeletal muscle.  Although lung volumes were not measured in the 
present study, it is possible that a decrease in DH may have also contributed to the 
improvement in endurance performance in response to exercise training with 
supplemental O2.   
A major limitation of the present study is the small sample size.  This was 
primarily due to the limited patient pool and the time commitment involved in 
participating in the study.  The present findings although interesting and provocative 
should be considered as preliminary.  More extensive research with a larger sample 
size should be undertaken before recommending the use of supplemental O2 during 
exercise training in patients with CF.  This preliminary study was designed primarily to 
assess the effect of supplemental O2 during exercise training on V7O2peak, O2uptake 
kinetics, endurance performance, and muscle strength in patients with CF.  
Considering that the study findings indicate a beneficial effect of using supplemental 
O2 during exercise training in CF, future studies should examine the putative 
mechanisms responsible for the enhance training benefits. 
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Summary 
Compared to 8 weeks of HIIT while breathing normal room air, 8 weeks of HIIT 
with supplemental O2 resulted in a greater improvement in training volume, O2uptake 
kinetics and endurance performance in patients with mild, moderate and severe CF.  
There was no change in V7O2peak, muscle strength or muscle endurance in either group 
in response to the training programme.  These finding,s although preliminary and 
based on a small sample size, indicate that the provision of supplemental O2 during 
exercise training may improve endurance capacity in patients with CF.   
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Chapter 6  
Conclusions and Recommendations 
The purpose of this research was to compare the exercise response in patients 
with different CF severities using non- invasive methods, and to examine the effect of 
exercise training with and without O2 supplementation on exercise performance.  
Preliminary evidence is also provided on the beneficial effect of supplemental O2 
during exercise in CF patients.   
The results provide important information on both submaximal and maximal 
exercise response in different CF severities.  Evidence is provided to indicate that peak 
exercise capacity is reduced in individuals with mild, moderate and severe CF 
compared to healthy controls.  Although the sample size was relatively small there was 
evidence that abnormal mechanical ventilation, reduced pulmonary gas exchange and 
reduced cardiovascular response may each contribute to exercise limitation in CF 
patients with FEV1 <30.  The internal and external validity of these findings can be 
strengthened by using a larger sample size, and employing more invasive techniques to 
investigate putative mechanisms.  For example, measuring DH, which is considered an 
indication of dynamic ventilatory mechanics may help to explain the reduction in 
VT/VC.  Therapies such us supplemental O2 and the use of inhaled bronchodilators 
before or during exercise partially reverses DH and may represent the first step in 
improving dyspnea and exercise capacity.  Future research is needed to provide a 
clinical validation of physiological concepts supporting the role of DH on functional 
status in CF.  
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Mechanical support ventilation is another intervention that may improve 
exercise tolerance in CF patients by allowing them to exercise at a higher exercise 
intensity level.  Unloading the respiratory muscle by mechanical support ventilation 
has been shown to improve blood flow and O2 transport to the contracting peripheral 
muscles while reducing quadriceps fatigability in athletes [61, 212].  The interaction 
between peripheral muscle function and unloading of the respiratory system is an area 
that requires further research in CF.   
In addition to O2 pulse, the measurement of ccardiovascular and pulmonary 
hemodynamics would provide a greater insight into the cardiovascular response to 
exercise in CF.  Echocardiography can provide information on CO and pulmonary 
pressure during exercise.  It may help to determine whether a pulmonary vascular 
response can be considered as a limiting factor in severe CF.   
Functional, morphological and biochemical alterations in skeletal muscle due 
primarily to physical inactivity have been shown to contribute to exercise intolerance 
in CF patients.  In addition, there is also evidence that the impaired exercise capacity in 
CF may be related that an intrinsic abnormality in muscle function independent of 
deconditioning.  For example, abnormal expression of CFTR in skeletal muscle is 
associated with a reduction in both aerobic and anaerobic metabolism.  The current 
study used non-invasive methods to assess muscle function, and was not designed to 
investigate the mechanism responsible for the alterations in muscle performance.  
Future studies using NMR spectroscopy or muscle biopsy samples should help to 
distinguish between muscle deconditioning and intrinsic muscle abnormality in CF.  In 
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addition, the morphological, biochemical and molecular changes in response to acute 
and chronic exercise in individuals with CF should be investigated.   
The improvement in endurance capacity and ventilatory response following 8 
weeks of exercise training with supplemental O2 is a novel finding and clinically 
relevant considering the importance of aerobic fitness in predicting morbidity and 
mortality.  However, the small sample size limits the external validity of the results.  
The study should be replicated with larger sample size.  In addition, the optimal 
training intensity, duration and frequency when using supplemental oxygen should be 
determined.  If the results of the present study can be replicated in adults, it would be 
interesting to evaluate the efficacy of supplemental oxygen in children.  The 
development of appropriate strategies to help maintain the training effect in CF should 
also be investigated.  
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Appendix A  
CONSENT FORM 
 
Protocol Title: 
 
Please tick the appropriate answer. 
 
I confirm that I have read and understood the Patient Information Leaflet dated 14 
October, 2007 attached, and that I have had ample opportunity to ask questions all of 
which have been satisfactorily answered.  
 

 Yes
 

 No 
 
I understand that my participation in this study is entirely voluntary and that I may 
withdraw at any time, without giving reason, and without this decision affecting my 
future treatment or medical care.  
 

 Yes
 

 No 
 
I understand that my records may be viewed by individuals with delegated authority 
from Beaumont Hospital  
 

 Yes
 

 No 
 
I understand that my identity will remain confidential at all times.   
 

 Yes
 

 No 
 
I am aware of the potential risks of this research study.  
 

 Yes 


 No 
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I have been given a copy of the Patient Information Leaflet and this Consent form for 
my records.  
 

 Yes
 

 No 
 
FUTURE USE OF ANONYMOUS DATA:   
I agree that I will not restrict the use to which the results of this study may be put.  I 
give my approval that unidentifiable data concerning my person may be stored or 
electronically processed for the purpose of scientific research.    
 

 Yes
 

 No 
 
 
 
Patient _________________________ ___________________ 
 Signature Name in block capitals 
 
Date:__________________________ 
 
To be completed by the Principal Investigator or his nominee.  
 
I the undersigned, have taken the time to fully explain to the above patient the nature 
and purpose of this study in a manner that he/she could understand. I have explained 
the risks involved, the experimental nature of the treatment, as well as the possible 
benefits and have invited him/her to ask questions on any aspect of the study that 
concerned them. 
 
 
________________ _____________________ _____________
 ________ 
Signature: Name in Block Capitals: Qualification:
 Date: 
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Appendix B  
SCREENING VISIT DATA 
 
Name:   ________________     Date: ______________ 
 
Subject ID: ________________ 
 
Date of Birth: ____/____/____     Age:             yrs                 
             
Informed consent signed:      
 
Medication list: 
Nebulized Medication: _______________________________________________ 
Inhaled Medication: _________________________________________________ 
Oral Medication: ____________________________________________________ 
Height: ______ cm      RHR:            bpm 
 
Weight: ______ kg      BP:            /              mmHg 
Skinfolds and % Body Fat Measurement 
Directions 
Use Cambridge Scientific Industries L Skinfold Calipers. 
Take measurements on right hand side of the body and rotate sites. 
 
Tester Name: ____________________                                   
 
 
Site 
 
1 
 
2 
 
3 
 
AVG 
Tricep      
Subscapular     
Chest     
Midaxillary     
Abdominal     
Suprailiac     
Thigh     
 
Sum of 7 AVG’s (X) 
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BD = 1.112 – 0.00043499(sum of 7 skinfolds) +   0.00000055(x)2 –   0.00028826(Age) 
X = Sum of 7 site AVG 
A = Age in years. 
BD=            .  
White males aged 20 – 80. BF% = ((4.95/body density) – 4.50) * 100 
White males aged 17 – 19. BF% = ((4.99/body density) – 4.55) * 100 
 
% Body Fat = 
 
% Lean Body Mass = 
 
Spirometry:     
  Absolute % Predicted 
FEV1:  _____      _____ 
FVC:  _____      _____ 
MVV  _____      _____ 
DLCO: _____      _____ 
 
Comments: 
 
 
 
 
 
 
 
Fasting 4 h   Yes  □ No  □ 
Resting blood sample:  Yes  □ No  □ 
Calibration:    Yes  □ No  □ 
O2 Adjust   Yes  □ No  □    
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Flowmeter (0.9-1.1)  Old __________  New __________ 
Gas Delay (1400-1700ms) Old __________  New __________ 
(Gas Delay variance should be no more than 20-40 ms) 
Print calibration:   Yes  □ No  □   
 
 
 
Protocol:  _______________________________ 
 
Stage Min Workloa
d 
RPE-L RPE-C RPE-O Lactate HR BP 
Rest 0-3        
Warm-
up 
3-6        
Exercise         
1 6-7        
2 7-8        
3 8-9        
4 9-10        
5 10-11        
6 11-12        
7 12-13        
8 13-14        
9 14-15        
10 15-16        
11 16-17        
12 17-18        
13 18-19        
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14 19-20        
15 20-21        
R2 22-23        
R5 25-26        
R7 28-29        
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Peak Data: 
Total time:   _________ sec    HR@ AT: _________ 
bpm 
Workload:   _________ Watts   %HR@AT _________ 
VO2:    _________ L/min   VO2@AT _________ L/min 
RER:    _________    %VO2@AT _________  
HR:    _________ bpm   WL@AT _________ Watts 
RPE-O:   _________    HR@ LT: _________ bpm 
Ve:   _________ L/min   %HR@LT _________ 
Lactate  _________ mmol/L   VO2@LT _________ L/min 
AT % VO2 predicted:  _________ l/min   %VO2@LT _________  
Comments:       WL@LT _________ Watts 
HR@ Vequiv: _________ 
bpm 
%HR@Vequiv _________ 
VO2@Vequiv _________ L/min 
%VO2@Vequiv _________ 
WL@Vequiv _________Watts 
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Appendix C  
SUBMAXIMAL TEST DATA COLLECTION 
 
Name:   ________________     Date: ______________ 
 
Subject ID: ________________ 
 
Date of Birth: ____/____/____     Age:             yrs                 
                 
 
Height: ______ cm      RHR:            bpm 
 
Weight: ______ kg      BP:            /              mmHg 
 
VO2 max _______ L/min 
 
Visit      ___________ 
55% VO2peak    □VO2(L/min) _________ Workload (W) _________ 
70% VO2peak:    □VO2(L/min) _________ Workload (W)
 _________ 
Self Selected Intensity:  □ VO2(L/min) _________ Workload (W) _________ 
 
Fasting 4 h   Yes  □ No  □ 
Resting blood sample:  Yes  □ No  □ 
Calibration:    Yes  □ No  □ 
O2 Adjust   Yes  □ No  □    
Flowmeter (0.9-1.1)  Old __________  New __________ 
Gas Delay (1400-1700ms) Old __________  New __________ 
(Gas Delay variance should be no more than 20-40 ms) 
Print calibration:   Yes  □ No  □   
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Comments: 
 
 
 
rotocol:  _______________________________ 
 
Stage Min Work 
load 
RPE-L RPE-C RPE-O Lactate HR BP 
Rest 0-3        
Exercise         
1 3-4        
2 4-5        
3 5-6        
4 6-7        
5 7-8        
6 8-9        
7 9-10        
8 10-11        
9 11-12        
10 12-13        
11 13-14        
15 17-18        
16 19-20        
20 22-23        
21 23-24        
25 27-28        
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30 32-33        
R2 35-36        
R5 38-39        
R7 41-42        
Comments: 
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Appendix D  
6 Minute Walk Test 
 
Equipment: 
1. Countdown timer 
2. Lap counter 
3. Two small cones to mark turnaround points 
4. Chair  
5. Worksheets 
6. O2 Source 
7. Telephone 
8. Defibrillator 
Patient Prep: 
1. Comfortable clothing 
2. Appropriate shoes 
3. Use of walking aids 
4. Light meal in early morning/afternoon before test ok 
5. No vigorous exercise 2 hours prior to test 
Measurement: 
1. Repeat tests should be performed at same time of day. 
2. No warm up period 
3. Sit resting 10 minutes prior. Check pulse, blood pressure, clothing and shoes 
4. Pulse oximetry is optional 
5. Stand patient and rate baseline dyspnea and overall fatigue using Borg scale. 
6. Set lap counter to 0 and timer to 6 minutes. 
7. Instruct patient as follows: 
a. The object of this test is to walk as far as possible for 6 minutes.  You 
will walk back and forth in this hallway.  Six minutes is a long time to 
walk so you will exert yourself.  You will probably get out of breath or 
become exhausted.  You are permitted to slow down, to stop and to 
rest as necessary.  You may lean against the wall while resting but 
resume walking as soon as you are able. 
b. You will be walking back and forth around the cones.  You should pivot 
briskly around the cones and continue back the other way without 
hesitation.  Now I’m going to show you, please watch the way I turn 
with no hesitation.   
c. Demonstrate by walking one lap 
d. Are you ready to do that?  I am going to use this counter to keep track 
of the number of laps you complete.  I will click it each time you turn 
around at this starting line.  Remember the object of this is to walk as 
far as possible or 6 minutes but don’t run or jog. 
e. Start on my countdown when you tell me you are ready. 
8. Position patient at start line.  Stand near the starting line, do not walk with the 
patient during the test. Start timer when patient begins to walk. 
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9. Do not talk to anyone during the walk, use even tone of voice and use standard 
phrases of encouragement.  Watch the patient. 
a. Tell patient minutes left and well done or good job.  Nothing more. 
b. If patient stops and needs rest, tell them they can lean against the wall 
and continue when they are able.  Do not stop the timer.  If they can not 
or will not continue take the chair to them to sit on and note the 
distance and time stopped and reason for stopping. 
10. When patient returns to the start line, click the counter or mark the paper. 
11. when timer is 15 seconds from end tell them in a moment you will tell them to 
stop, they should stop where they are and you should go to them.  When timer 
ends tell them to stop, go to the patient and take the chair if necessary.  Mark 
the spot with paper or object 
12. Record the post walk dyspnea and fatigue levels 
13. If using oximeter, measure then remove 
14. Record the number of laps from counter 
15. Record additional distance as number of meters.  Calculate total distance 
walked to nearest meter and record on worksheet 
16. Congratulate patient on their effort and offer a drink of water. 
 
6 Minute Walk Test Report   
 
Date: ____/_____/_____      Time  
 
 
Lap counter    __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ 
 
Patient name:  __________________________________ 
Patient ID: __________________________________ 
 
Gender: M  / F 
Age:  ________ 
Height  ________cm 
Weight ________kg 
BP  ______/______ 
Medications taken before the test (dose and time): ___________________________ 
Supplemental oxygen during the test:   NO / YES, flow_______L/min, 
type_______ 
 
 Baseline End of Test  
Time    
Heart Rate    
Dyspnea   Borg scale 
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Fatigue   Borg scale 
Lactate (before and 
1 minute after) 
   
SpO2%   % 
 
Stopped or paused before 6 minutes?  NO YES, 
reason:________________ 
 
Other symptoms at end of exercise: angina  dizziness hip, leg, calf pain 
 
Number of Laps: _________ (x 60 meters)  +  final partial lap: ________meters = 
 
Total distance walked in 6 minutes: _____________meters 
 
Predicted distance:  ________meters  Percent predicted: ______% 
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Comments: 
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Appendix E  
CF Training Programme 
 
Name                                                                                                                 Date 
 
Subject ID  
 
Informed consent form signed 
 
Medication 
 
Hospitalization  
 
Peak Data 
 
Work Rate                     Watts                    Anaerobic Threshold (watts) 
 
Heart Rate                     B/min                    Lactate threshold (watts) 
 
VO2                                               l/min 
 
Ventilation                     l/min 
 
SPO2                                            % 
 
 
Target training Intensity (70% PWR) 
 
Work Rate                        Watts 
 
Heart Rate                        B/min 
 
VO2                                                  l/min 
 
Ventilation                       l/min 
 
SPO2                                               % 
 
Comments 
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Rest     
Sessions HR SPO2 BP 
    
    
    
    
    
    
    
    
    
Exercise intervals 
sessions  Time W
R 
HR SPO
2 
RPE 
O 
RPE 
C 
RPE L Lactate 
1 warm  5        
 exercise 0-2        
 recovery 2-3        
2          
 exercise 3-5        
 recovery 5-6        
3          
 exercise 6-8        
 recovery 8-9        
4            
 exercise 9-11        
 recovery 11-12        
5           
 exercise 12-14        
 recovery 14-15        
6          
 exercise 15-17        
 recovery 17-18        
7          
 exercise 18-20        
 recovery 20-21        
8           
 exercise 21-23        
 recovery 23-24        
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Exercise intervals 
sessions  Time W
R 
HR SPO2 RPE 
O 
RPE 
C 
RPE 
L 
Lactate 
9          
 exercise 24-26        
 recovery 26-27        
10          
 exercise 27-29        
 recovery 29-30        
11          
 exercise 30-32        
 recovery 32-33        
12          
 exercise 33-35        
 recovery 35-36        
13          
 exercise 36-38        
 recovery 38-39        
14          
 exercise         
 recovery         
15          
 exercise         
 recovery         
16          
 exercise         
 recovery         
 
 
